{
    "items": "209",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss, Improved Metabolic Markers, Liver Fat Reduction in HIV-Related Liver Disease - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37515493/novo-nordisks-semaglutides-multi-beneficial-effects-weight-loss-improved-metabolic-markers-liver-",
            "time_published": "20240306T171743",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease, as unveiled by data from a mid-stage study sponsored by the National Institutes of Health.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.004818,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.313484",
                    "ticker_sentiment_score": "0.162629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dexcom Pops As It Enters A New CGM Market: Non-Diabetics",
            "url": "https://www.investors.com/news/technology/dexcom-stock-continuous-glucose-monitor-stelo/",
            "time_published": "20240306T152500",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/03/Stock-dexcom-one-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.94762"
                }
            ],
            "overall_sentiment_score": 0.250101,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.2163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.176098",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.457794",
                    "ticker_sentiment_score": "0.179837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.2163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37510490/escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk",
            "time_published": "20240306T143330",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and \"finishing\" of its injector pens.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.042218,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.601928",
                    "ticker_sentiment_score": "-0.035373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "-0.090714",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Down Despite Kidney Outcomes Study Success",
            "url": "https://www.zacks.com/stock/news/2236532/novo-nordisk-nvo-down-despite-kidney-outcomes-study-success",
            "time_published": "20240306T133400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.040863,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.211688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.479683",
                    "ticker_sentiment_score": "0.076889",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACET",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.021173",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?",
            "url": "https://www.fool.com/investing/2024/03/06/is-it-time-to-buy-3-worst-performing-dow-jones/",
            "time_published": "20240306T124500",
            "authors": [
                "James Brumley"
            ],
            "summary": "It's only a bargain price if it's actually worth owning.",
            "banner_image": "https://media.ycharts.com/charts/7fb30c655c00f3cdce543ba9f078e851.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.086469,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SPLK",
                    "relevance_score": "0.073773",
                    "ticker_sentiment_score": "0.094378",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.028008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.085291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.112615",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "-0.019421",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.085291",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?",
            "url": "https://www.fool.com/investing/2024/03/06/is-viking-therapeutics-stock-a-better-buy-than-eli/",
            "time_published": "20240306T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768024/scientists-smiling-and-shaking-hands.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.209691,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.63878",
                    "ticker_sentiment_score": "0.405744",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.207258",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.603465",
                    "ticker_sentiment_score": "0.395508",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday",
            "url": "https://www.fool.com/investing/2024/03/05/why-novo-nordisk-stock-tumbled-by-nearly-3-on-tues/",
            "time_published": "20240305T232300",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The hotly popular European pharmaceutical company continues to investigate how its most popular molecule can be used for different afflictions.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768182/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.047843,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.140896",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.522333",
                    "ticker_sentiment_score": "-0.16977",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/news/24/03/37495723/bidens-state-of-the-union-grading-his-results-on-abortion-access-drug-prices-and-opium-epidemic",
            "time_published": "20240305T214503",
            "authors": [
                "Natan Ponieman"
            ],
            "summary": "As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/joe-biden-shutter4_9.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.140317,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update",
            "url": "https://www.prnewswire.com/news-releases/rigel-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302080342.html",
            "time_published": "20240305T210100",
            "authors": [
                "Inc.",
                "Rigel Pharmaceuticals"
            ],
            "summary": "SOUTH SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSEÂ® ( fostamatinib disodium hexahydrate ) tablets for the treatment of ...",
            "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.014494,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GRFS",
                    "relevance_score": "0.044441",
                    "ticker_sentiment_score": "0.053799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KSPHF",
                    "relevance_score": "0.014821",
                    "ticker_sentiment_score": "0.025558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIGL",
                    "relevance_score": "0.132774",
                    "ticker_sentiment_score": "0.041199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.014821",
                    "ticker_sentiment_score": "-0.009142",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Are Dialysis Provider Stocks Trading Higher On Tuesday? - Fresenius Medical Care  ( NYSE:FMS ) , DaVita  ( NYSE:DVA ) ",
            "url": "https://www.benzinga.com/news/large-cap/24/03/37492500/why-are-dialysis-provider-stocks-trading-higher-on-tuesday",
            "time_published": "20240305T202124",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-Insulin-Injection-Pen-Or-Insulin_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.098581,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAX",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "-0.011285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.140076",
                    "ticker_sentiment_score": "0.146605",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "0.014182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "-0.011285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.519739",
                    "ticker_sentiment_score": "0.137878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.40348",
                    "ticker_sentiment_score": "-0.244003",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ozempic Is a Brain Drug",
            "url": "https://www.theatlantic.com/health/archive/2024/03/ozempic-glp1-weight-loss-brain-gut/677645/",
            "time_published": "20240305T175817",
            "authors": [
                "Sarah Zhang"
            ],
            "summary": "When scientists first created the class of drugs that includes Ozempic, they told a tidy story about how the medications would work: The gut releases a hormone called GLP-1 that signals you're full, so a drug that mimics GLP-1 could do the exact same thing, helping people eat less and lose weight.",
            "banner_image": "https://cdn.theatlantic.com/thumbor/PFdox4gfprgTZ5iIVHiZ6Iv3IjA=/0x0:2048x1152/960x540/media/img/mt/2024/03/ozempic_003/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.107155,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.017216",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "U.S. Stocks Aren't The Only Game In Town, Arm And Novo Please Investors",
            "url": "https://www.investors.com/research/arm-stock-novo-nordisk-foreign-stocks-to-buy-and-watch/",
            "time_published": "20240305T175500",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Looking outside the U.S., 10 names appear in IBD's Global Leaders screen of the IBD Stock Screener, a select list of foreign stocks with strong fundamentals that trade in the U.S. stock market. Arm stock and Novo Nordisk stand out.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-Arm-CPU-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.207827,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "-0.250562",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.22421",
                    "ticker_sentiment_score": "0.232278",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.364987",
                    "ticker_sentiment_score": "0.321466",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.150592",
                    "ticker_sentiment_score": "-0.042606",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?",
            "url": "https://www.fool.com/investing/2024/03/05/a-new-competitor-to-wegovy-could-be-on-the-way-sho/",
            "time_published": "20240305T161600",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Here's why I'm not worried.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767194/physician-shaking-patients-hand.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.140675,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.388018",
                    "ticker_sentiment_score": "0.010855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.062003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.207646",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.019648",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News",
            "url": "https://www.investors.com/news/technology/davita-stock-novo-nordisk-weight-loss-drug-dialysis/",
            "time_published": "20240305T154000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-DaVita-01-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.012189,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.157505",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.093653",
                    "ticker_sentiment_score": "0.267198",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.589793",
                    "ticker_sentiment_score": "0.190103",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362065",
                    "ticker_sentiment_score": "0.144641",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bitcoin To Hit $150K By Year-End, Says Fundstrat's Tom Lee: '...A Beeline Back Towards Its Long-Term Trend Line'; Apple's iPhone Sales Dip 24% in China, Falls to Fourth Place Behind Vivo and Huawei - Top Headlines Today While US Was Sleeping",
            "url": "https://www.benzinga.com/news/24/03/37485322/bitcoin-to-hit-150k-by-year-end-says-fundstrats-tom-lee-a-beeline-back-towards-its-long-term-trend-l",
            "time_published": "20240305T151426",
            "authors": [
                "Akanksha Bakshi"
            ],
            "summary": "Bitcoin's Rally Captures El Salvador President Nayib Bukele's Attention, Holds The Line With Memes Bitcoin Could Hit $200K This Year, Says Bitwise CIO: 'There's Too Much Demand And Not Enough Supply' Gold Bull Peter Schiff Raises Red Flag For BTC Rally: 'If I Was Long Bitcoin, I Would Be Worried ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bitcoin-Ethereum-Dogecoin_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.122735,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.103331",
                    "ticker_sentiment_score": "-0.167064",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AVDL",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.246662",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.142493",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "-0.112499",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.05211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AROW",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PAY",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.135491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.142493",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.103331",
                    "ticker_sentiment_score": "-0.016823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHUN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.417978",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.285753",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKLA",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.245161",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:SHIB",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "0.002753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:DOGE",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "-0.226374",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why",
            "url": "https://www.fool.com/investing/2024/03/05/eli-lilly-and-novo-nordisk-could-just-be-getting/",
            "time_published": "20240305T145300",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767512%2Fstatistic_id271464_diabetics-prevalence-worldwide-2021-2030-and-2045.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.221674,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.41627",
                    "ticker_sentiment_score": "0.367741",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.187892",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.506613",
                    "ticker_sentiment_score": "0.285938",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point",
            "url": "https://www.zacks.com/stock/news/2235993/new-to-investing-this-1-medical-stock-could-be-the-perfect-starting-point",
            "time_published": "20240305T143007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default267.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99489"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.341907,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.194763",
                    "ticker_sentiment_score": "0.22091",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial",
            "url": "https://www.cnbc.com/2024/03/05/novo-nordisk-ozempic-cuts-risk-of-kidney-disease-progression.html",
            "time_published": "20240305T134737",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107378878-1709042046171-gettyimages-1741637270-AFP_33YW8FQ.jpeg?v=1709042239&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.014799,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.268294",
                    "ticker_sentiment_score": "0.192941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk says Ozempic helped patients with Type 2 diabetes in one new way",
            "url": "https://www.marketwatch.com/story/novo-nordisk-says-ozempic-reduced-risk-of-kidney-problems-by-24-in-patients-with-type-2-diabetes-f17170bc",
            "time_published": "20240305T132000",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "The company is planning to file for regulatory approval of a label expansion for Ozempic in the U.S. and European Union in 2024.",
            "banner_image": "https://images.mktw.net/im-74470623/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.076158,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.050374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "-0.214583",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "-0.065299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.257442",
                    "ticker_sentiment_score": "-0.068976",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Novo Nordisk Stock Today? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37478859/novo-nordisk-says-famed-diabetes-medicine-ozempic-reduces-risk-of-kidney-disease-progression-data",
            "time_published": "20240305T124145",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.026239,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.61135",
                    "ticker_sentiment_score": "0.109061",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How a pharma company is helping transform health of Denmark's economy",
            "url": "https://www.moneycontrol.com/news/opinion/how-a-pharma-company-is-helping-transform-health-of-denmarks-economy-12406931.html",
            "time_published": "20240305T114236",
            "authors": [],
            "summary": "The success of Novo Nordisk -- makers of Ozempic and Wegovy, shows the outsized effect a single company can have on a nation ...",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/03/408424206.jpg",
            "source": "Money Control",
            "category_within_source": "Economy",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.239232,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "-0.013961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NRHI",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "0.079885",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.15347",
                    "ticker_sentiment_score": "0.103555",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.102668",
                    "ticker_sentiment_score": "0.12222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "0.111455",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Healthcare Mutual Funds to Buy as the Sector Continues to Grow",
            "url": "https://www.zacks.com/stock/news/2235755/3-healthcare-mutual-funds-to-buy-as-the-sector-continues-to-grow",
            "time_published": "20240305T112400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "JFNAX, VGHCX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dc/1715.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.164148,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JHG",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.188987",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.088956",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.008009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.060929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.074011",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - AIM International Mutual Funds",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840228/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
            "time_published": "20240305T110100",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.124283,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "0.262306",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Invesco Ltd.",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840224/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
            "time_published": "20240305T110000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.041462,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840191/0/en/Novo-Nordisk-A-S-Semaglutide-1-0-mg-demonstrates-24-reduction-in-the-risk-of-kidney-disease-related-events-in-people-with-type-2-diabetes-and-chronic-kidney-disease-in-the-FLOW-tri.html",
            "time_published": "20240305T095300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 5 March 2024 - Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": -0.066871,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.055621",
                    "ticker_sentiment_score": "0.038043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.055621",
                    "ticker_sentiment_score": "0.038043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.324495",
                    "ticker_sentiment_score": "0.004748",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' - NVIDIA  ( NASDAQ:NVDA ) , Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37474512/jim-cramer-says-nvidia-eli-lilly-novo-nordisk-are-not-overvalued-will-be-ready-to-buy-if-this-ma",
            "time_published": "20240305T063337",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.248444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.227008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.264682",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.227008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cramer says get ready to buy if there's a market sell-off: 'I have my shopping list'",
            "url": "https://www.cnbc.com/2024/03/04/jim-cramer-says-get-ready-to-buy-if-theres-a-market-sell-off.html",
            "time_published": "20240305T000845",
            "authors": [
                "Julie Coleman"
            ],
            "summary": "CNBC's Jim Cramer named Nvidia, Eli Lilly and Novo Nordisk as companies that deserve high valuations.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107382151-1709596549MM-A-030424-short.jpg?v=1709596548&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.12097,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "-0.092774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "-0.022109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "0.123273",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The battle over the trillion-dollar weight-loss bonanza",
            "url": "https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza",
            "time_published": "20240304T210358",
            "authors": [
                "The Economist"
            ],
            "summary": "W drugs called -1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20240309_EPC678.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.077222,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.02493",
                    "ticker_sentiment_score": "0.02801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.02493",
                    "ticker_sentiment_score": "0.03395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.02493",
                    "ticker_sentiment_score": "0.06469",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.02493",
                    "ticker_sentiment_score": "-0.029003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.070341",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.02493",
                    "ticker_sentiment_score": "0.02801",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What the Options Market Tells Us About Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37460848/what-the-options-market-tells-us-about-novo-nordisk",
            "time_published": "20240304T161708",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Novo Nordisk NVO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.068909,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.709186",
                    "ticker_sentiment_score": "0.262934",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/03/04/2839692/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240304T142900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 04 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.12545,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.200514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Is the Biggest Company Not in the \"Magnificent Seven\" -- but It Deserves to Be",
            "url": "https://www.fool.com/investing/2024/03/04/big-company-not-in-magnificent-seven-lilly/",
            "time_published": "20240304T095500",
            "authors": [
                "James Brumley"
            ],
            "summary": "It's in a distinctly different business than the \"Magnificent Seven\" companies, but it deserves the same attention.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767518%2F022924-eli-lilly-results.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.305234,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.46341",
                    "ticker_sentiment_score": "0.414854",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.139985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.127166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.071754",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.104019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2024/03/03/blockbuster-drug-stock-novo-nordisk-vs-eli-lilly/",
            "time_published": "20240303T175100",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This is a close contest, and it'll go on for at least a few more rounds.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766405/investor-considers-writing-on-glass-wall-while-another-sits-in-the-background.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.294216,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.244637",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.351273",
                    "ticker_sentiment_score": "0.375129",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Ginkgo Bioworks Destined to Be in a \"Magnificent Seven\" of Healthcare Stocks?",
            "url": "https://www.fool.com/investing/2024/03/03/is-ginkgo-bioworks-destined-to-be-in-magnificent/",
            "time_published": "20240303T174500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It isn't ready for membership today, but it could have a path in the future.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766847/investor-thinks-while-looking-out-a-window.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.220958,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.159569",
                    "ticker_sentiment_score": "0.093307",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.053509",
                    "ticker_sentiment_score": "0.226829",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.211652",
                    "ticker_sentiment_score": "0.152627",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053509",
                    "ticker_sentiment_score": "0.226829",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.053509",
                    "ticker_sentiment_score": "0.226829",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite",
            "url": "https://www.fool.com/investing/2024/03/03/ozempic-wont-sink-this-medical-device-stock/",
            "time_published": "20240303T144500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "There is a world of opportunities ahead for this healthcare giant.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767012/diabetes-patient-adjusting-device.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.172452,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.16317",
                    "ticker_sentiment_score": "0.224353",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.11313",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.369163",
                    "ticker_sentiment_score": "0.335658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics emerges as a strong weight loss drug player - or takeover target",
            "url": "https://www.cnbc.com/2024/03/03/weight-loss-drugs-viking-therapeutics-emerges-as-competitor.html",
            "time_published": "20240303T124821",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Some Wall Street analysts said Viking's experimental obesity treatment may be \"best-in-class\" following the release of midstage trial data.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/106851374-16153086162021-03-09t164836z_332945025_rc2s7m9h160o_rtrmadp_0_health-elililly.jpeg?v=1709322907&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.083679,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.187072",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.024622",
                    "ticker_sentiment_score": "0.036869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.024622",
                    "ticker_sentiment_score": "0.145402",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.024622",
                    "ticker_sentiment_score": "0.082228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122643",
                    "ticker_sentiment_score": "0.10614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.024622",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.",
            "url": "https://www.fool.com/investing/2024/03/03/missed-out-on-novo-nordisk-stock-buy-this-1-biotec/",
            "time_published": "20240303T124100",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The battle for the obesity therapies market is escalating.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767199/scientist-looking-at-microscope-in-lab.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.245163,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.209365",
                    "ticker_sentiment_score": "0.353304",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.209365",
                    "ticker_sentiment_score": "0.157533",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Magnificent Growth Stocks to Buy in March",
            "url": "https://www.fool.com/investing/2024/03/02/3-magnificent-growth-stocks-to-buy-in-march/",
            "time_published": "20240302T143000",
            "authors": [
                "and Prosper Junior Bakiny",
                "David Jagielski",
                "Keith Speights"
            ],
            "summary": "These three stocks have two important common denominators: the same industry and tremendous growth prospects.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767491/happy-woman-because-the-stock-market-went-up.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.211721,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.24374",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.240059",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.344473",
                    "ticker_sentiment_score": "0.130278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.153986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044469",
                    "ticker_sentiment_score": "0.060995",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy Eli Lilly Stock Now?",
            "url": "https://www.fool.com/investing/2024/03/02/is-it-too-late-to-buy-eli-lilly-stock-now/",
            "time_published": "20240302T131500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly stock is having a moment, but the company could easily continue soaring.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766723%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.250494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.539306",
                    "ticker_sentiment_score": "0.300425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "0.10883",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Opinion | Why stock market stars are at odds with real world's investment needs",
            "url": "https://www.scmp.com/comment/opinion/article/3253671/why-stock-market-stars-are-odds-real-worlds-investment-needs",
            "time_published": "20240302T083011",
            "authors": [
                "Anthony Rowley"
            ],
            "summary": "Investors around the world have been dazzled by the performance of the \"Magnificent Seven\" US tech stocks and, to a lesser degree, Europe's \"Granolas\". The size and influence of these giants are taking investment away from essential socioeconomic causes such as climate change, infrastructure and ...",
            "banner_image": "https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2024/03/01/1f241530-f128-4a24-823f-61fc08a0f44e_cbee1442.jpg",
            "source": "South China Morning Post",
            "category_within_source": "Economy",
            "source_domain": "www.scmp.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.095661,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.283573",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.283573",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.283573",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "-0.103878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "-0.103878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "-0.103878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "-0.103878",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "-0.103878",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What China can learn from the ashes of my boat",
            "url": "https://www.ft.com/content/3dec1977-84cd-484b-8c03-37e03b1ec2f7",
            "time_published": "20240302T050007",
            "authors": [
                "Stuart Kirk"
            ],
            "summary": "Not a day passes without me screaming at televisions, pepper grinders, lawnmowers or Tupperware. Such poor design. So badly executed. If only Steve Jobs or Sir James Dyson had made you, damn it! Hence my sadness at the news that Apple cars will remain a dream.",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F54fafeb1-cfd3-46bf-98f7-e422c33b66b0.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": -0.080784,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.050894",
                    "ticker_sentiment_score": "0.144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.050894",
                    "ticker_sentiment_score": "0.066938",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050894",
                    "ticker_sentiment_score": "0.066938",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Topped the Market Today",
            "url": "https://www.fool.com/investing/2024/03/01/why-novo-nordisk-stock-topped-the-market-today/",
            "time_published": "20240301T231521",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A favorite of both investors and analysts gets a boost from a bullish move by a pundit.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767701/medical-professional-holding-dollar-sign-paperweight.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.370256,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.117486",
                    "ticker_sentiment_score": "0.180181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.624759",
                    "ticker_sentiment_score": "0.546133",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Judge upholds Medicare drug price negotiation program | Politics",
            "url": "https://www.cnn.com/2024/03/01/politics/medicare-drug-price-negotiation-astrazeneca/index.html",
            "time_published": "20240301T215800",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "Judge upholds Medicare drug price negotiation program, but more lawsuits are being considered in other courts ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2020-05-28t000000z-1591044181-rc2vxg9ujy9p-rtrmadp-3-health-prescriptions-copy.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.026988,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.293038",
                    "ticker_sentiment_score": "0.065582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.119532",
                    "ticker_sentiment_score": "0.088629",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "-0.037122",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings - Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37433073/shareholder-alert-levi-korsinsky-llp-notifies-investors-of-an-investigation-into-the-fairness-of-t",
            "time_published": "20240301T215743",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Catalent, Inc. ( \"Catalent\" or the \"Company\" ) CTLT stock purchased prior to February 16, 2024.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.00718,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.83383",
                    "ticker_sentiment_score": "0.077772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.044259",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37430399/eli-lillys-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-increti",
            "time_published": "20240301T204459",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "BofA Securities says Eli Lilly and Company LLY remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% ( compared to the DRG index's +10% ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.412925,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.597525",
                    "ticker_sentiment_score": "0.545815",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.324495",
                    "ticker_sentiment_score": "0.432372",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Judge rejects AstraZeneca's challenge to Medicare drug price negotiations",
            "url": "https://www.cnbc.com/2024/03/01/medicare-drug-price-negotiations-judge-rejects-astrazeneca-challenge.html",
            "time_published": "20240301T190250",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1709317769&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.026892,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.250416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How investors can ride along as a global commodity market shifts away from China",
            "url": "https://www.marketwatch.com/story/heres-how-investors-can-ride-along-as-a-major-global-commodity-market-shifts-away-from-china-2d122885",
            "time_published": "20240301T175200",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "China has long dominated the world market for rare earth minerals, which are required components of many devices.",
            "banner_image": "https://images.mktw.net/im-99051667?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999995"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.092941,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "0.119251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.255928",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.112357",
                    "ticker_sentiment_score": "0.088038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "-0.022334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "0.047489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.149424",
                    "ticker_sentiment_score": "-0.008163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.102997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "-0.136767",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.112357",
                    "ticker_sentiment_score": "0.164847",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.124097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.102997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.037563",
                    "ticker_sentiment_score": "-0.068027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.075043",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-price-target-increase-weight-loss-drugs-obesity-treatment/",
            "time_published": "20240301T163500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                }
            ],
            "overall_sentiment_score": 0.126199,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.803345",
                    "ticker_sentiment_score": "0.271135",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.019112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRWD",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "-0.16103",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.019112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.180236",
                    "ticker_sentiment_score": "0.087193",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Ginkgo Bioworks Stock Is Down After Earnings - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ",
            "url": "https://www.benzinga.com/news/earnings/24/03/37423703/why-ginkgo-bioworks-stock-is-down-after-earnings",
            "time_published": "20240301T153449",
            "authors": [
                "Erica Kollmann"
            ],
            "summary": "Ginkgo Bioworks Holdings, Inc. DNA shares are trading lower Friday after the company posted worse-than-expected fourth-quarter results and issued disappointing guidance. The company reported quarterly losses of 11 cents per share which missed the analyst consensus estimate of losses of 10 cents.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ginkgo-DNA.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.158382,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "0.018916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.632565",
                    "ticker_sentiment_score": "0.196699",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "0.216142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "0.216142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What the Options Market Tells Us About Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37423663/what-the-options-market-tells-us-about-novo-nordisk",
            "time_published": "20240301T153220",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.073453,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.689912",
                    "ticker_sentiment_score": "0.156979",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years",
            "url": "https://www.fool.com/investing/2024/03/01/2-stocks-that-could-turn-1000-into-2500-in-5-years/",
            "time_published": "20240301T123100",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "It will take a lot, but this goal isn't out of reach for these stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766641/patient-sitting-on-hospital-bed.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.223574,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.441059",
                    "ticker_sentiment_score": "0.168395",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KRYS",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.132994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.052919",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Transamerica Mutual Funds for Superb Returns",
            "url": "https://www.zacks.com/stock/news/2234375/3-transamerica-mutual-funds-for-superb-returns",
            "time_published": "20240301T121800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invests in Transamerica mutual funds like TWQZX, TIHJX and TLATX for rewarding returns.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.216795,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MITSF",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COP",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.047083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.047083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMFG",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.05009",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 4 Stocks Are the \"Magnificent Seven\" of Healthcare",
            "url": "https://www.fool.com/investing/2024/03/01/these-stocks-are-magnificent-seven-of-healthcare/",
            "time_published": "20240301T065900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Their growth trajectories aren't as meteoric, but they're still notable.",
            "banner_image": "https://media.ycharts.com/charts/13eb85c054da9d0aa6615994f237628d.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.27987,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.028625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.154565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.188971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.154565",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.083806",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.155786",
                    "ticker_sentiment_score": "0.137514",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Europe is having its worst earnings season since the onset of Covid - with little hope of a quick turnaround",
            "url": "https://www.cnbc.com/2024/03/01/europe-is-having-its-worst-earnings-season-since-the-onset-of-covid.html",
            "time_published": "20240301T060612",
            "authors": [
                "Silvia Amaro"
            ],
            "summary": "Looking forward to the next reporting season, however, strategists are pessimistic on the tide turning.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107378750-17090226921709022690-33497022681-1080pnbcnews.jpg?v=1709022691&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.012183,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "-0.0921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.1042",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity drugs will not solve our billion-person problem, warns WHO | World News",
            "url": "https://www.business-standard.com/world-news/obesity-drugs-will-not-solve-our-billion-person-problem-warns-who-124030100076_1.html",
            "time_published": "20240301T012208",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Obesity drugs will not solve our billion-person problem, warns WHO Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/01/full/1709255982-6513.png?im=Resize=(640,480)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004832,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "-0.067033",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?",
            "url": "https://www.marketwatch.com/story/granolas-vs-the-magnificent-seven-which-should-you-dig-into-now-79d2aaf5",
            "time_published": "20240229T234400",
            "authors": [
                "Mark Hulbert"
            ],
            "summary": "These European and U.S. market darlings both come with spectacular trailing returns, overvaluation and investors' FOMO.",
            "banner_image": "https://images.mktw.net/im-68278160?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.238065,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.120865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.164187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.164187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.164187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.039745",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.151593",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.039745",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.164187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.203935",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.039745",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.035999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.035999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.039745",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/news/24/02/37404119/heres-how-much-100-invested-in-novo-nordisk-10-years-ago-would-be-worth-today",
            "time_published": "20240229T200032",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 7.05% on an annualized basis producing an average annual return of 17.5%. Currently, Novo Nordisk has a market capitalization of $536.06 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Could These 3 Companies Headline a \"Magnificent Seven\" of Biotech Stocks?",
            "url": "https://www.fool.com/investing/2024/02/29/could-these-3-companies-headline-magnificent-seven/",
            "time_published": "20240229T140000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These stocks meet many of the criteria long-term investors look for.",
            "banner_image": "https://media.ycharts.com/charts/a0139fd0df9b9ac5ba1cc3d6745e3b8b.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.303241,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.442767",
                    "ticker_sentiment_score": "0.443683",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.163124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.442767",
                    "ticker_sentiment_score": "0.372147",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK",
            "url": "https://www.zacks.com/stock/news/2233717/pharma-stock-roundup-fda-priority-tag-to-sny-abbv-filings-chmp-nod-for-azn-jnj-mrk",
            "time_published": "20240229T135000",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.162872,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.188761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.147818",
                    "ticker_sentiment_score": "0.062348",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "0.166116",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "-0.124137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "-0.119146",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.098862",
                    "ticker_sentiment_score": "0.095068",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-takes-advantage-of-soaring-stock-price-to-issue-fresh-shares-at-a-discount-5eb2a7fe",
            "time_published": "20240229T125500",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Viking Therapeutics has a stock offering starting at $85 - a discount from its Wednesday closing price of $94.50.",
            "banner_image": "https://images.mktw.net/im-454574/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.231491,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "-0.058797",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.34081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.050801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "-0.058797",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics: A Teachable Moment About Investing for the Long Term",
            "url": "https://www.fool.com/investing/2024/02/29/viking-therapeutics-a-teachable-moment-about-inves/",
            "time_published": "20240229T124500",
            "authors": [
                "George Budwell"
            ],
            "summary": "The biotherapeutics company's weight loss candidate scored a major win this week.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767179%2Frocket.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.03876,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "0.14684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.098366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "0.14684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "-0.056334",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?",
            "url": "https://www.fool.com/investing/2024/02/29/viking-soared-120-percent-is-it-a-buy/",
            "time_published": "20240229T114200",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Viking stock surged in the triple digits in one trading session.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767161%2Fgettyimages-1226994628.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.149498,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.150278",
                    "ticker_sentiment_score": "0.129045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.100518",
                    "ticker_sentiment_score": "0.058149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.163047",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150278",
                    "ticker_sentiment_score": "0.129045",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sarepta Therapeutics  ( SRPT )  Q4 2023 Earnings Call Transcript",
            "url": "https://www.fool.com/earnings/call-transcripts/2024/02/29/sarepta-therapeutics-srpt-q4-2023-earnings-call-tr/",
            "time_published": "20240229T050016",
            "authors": [
                "Motley Fool Transcribing"
            ],
            "summary": "SRPT earnings call for the period ending December 31, 2023.",
            "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.267153,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "0.06641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "0.096453",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "0.096453",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.009632",
                    "ticker_sentiment_score": "0.216298",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.038515",
                    "ticker_sentiment_score": "0.085822",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "0.096453",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "-0.025562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.004816",
                    "ticker_sentiment_score": "0.096453",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "InnovationRx: Exploring The Future Of Healthcare AI",
            "url": "https://www.forbes.com/sites/katiejennings/2024/02/28/innovationrx-exploring-the-future-of-healthcare-ai/",
            "time_published": "20240228T221912",
            "authors": [
                "Alex Knapp"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. reetings from Los Angeles, where health industry executives, startup founders and investors gathered at the ViVE conference.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65dfaf39f3e15d8eac74e26c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.069153,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALHC",
                    "relevance_score": "0.033515",
                    "ticker_sentiment_score": "0.068393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.067086",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABSI",
                    "relevance_score": "0.033515",
                    "ticker_sentiment_score": "0.054505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.033515",
                    "ticker_sentiment_score": "-0.012636",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.033515",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.033515",
                    "ticker_sentiment_score": "-0.012636",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Granolas 11 Vs. Magnificent 7: Low Volatility, Higher Yields - AstraZeneca  ( NASDAQ:AZN ) , ASML Holding  ( NASDAQ:ASML ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/37373981/11-granolas-stocks-outperform-magnificent-7-with-lower-volatility-higher-yields",
            "time_published": "20240228T194326",
            "authors": [
                "Stjepan Kalinic"
            ],
            "summary": "While many of the world's investors remain focused on \"The Magnificent Seven\" - a group of tech stocks that significantly outperformed in 2023 - a small group of European stocks has quietly outperformed most of the world.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eu-Flag-Waving-In-Front-Of-European-Parl.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999995"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.238898,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CHDRF",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.09879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SAP",
                    "relevance_score": "0.064536",
                    "ticker_sentiment_score": "-0.038301",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "0.041974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064536",
                    "ticker_sentiment_score": "0.148167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMSWA",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "-0.036811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.071263",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.09879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.148409",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.064536",
                    "ticker_sentiment_score": "0.051624",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.094629",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.064536",
                    "ticker_sentiment_score": "0.129363",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.064536",
                    "ticker_sentiment_score": "0.184755",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.032294",
                    "ticker_sentiment_score": "0.082708",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT - Altimmune  ( NASDAQ:ALT ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37373423/rosen-global-investor-counsel-encourages-altimmune-inc-investors-to-inquire-about-securities-class",
            "time_published": "20240228T191800",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. ALT resulting from allegations that Altimmune may have issued materially misleading business ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.135572,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.449219",
                    "ticker_sentiment_score": "0.142588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "-0.034518",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' weight loss drug showed faster results in clinical trials than Ozempic or Wegovy. Here's how it works.",
            "url": "https://www.businessinsider.com/viking-therapeutics-weight-loss-drug-ozempic-glp-1-agonists-2024-2",
            "time_published": "20240228T182900",
            "authors": [
                "Gabby Landsverk"
            ],
            "summary": "Viking Therapeutics weight loss drug works faster than Ozempic in trial - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.071606,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.252114",
                    "ticker_sentiment_score": "0.194458",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.139425",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say - Viking Therapeutics  ( NASDAQ:VKTX ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37369830/viking-therapeutics-weight-loss-study-data-outperformed-novo-nordisk-eli-lilly-stud",
            "time_published": "20240228T170535",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Viking Therapeutics Inc VKTX recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 demonstrated statistically significant reductions in body weight compared with placebo. The San Diego-based company also announced a capital raise of $350 ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.19441,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.030048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.23995",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.030048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' weight-loss drug data makes company takeover target",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-promising-weight-loss-drug-data-makes-the-company-a-takeover-target-5190434e",
            "time_published": "20240228T161800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Viking Therapeutics Inc.'s stock rose another 8% Wednesday to extend its week-to-date gains to 145%, as analysts weighed in on its positive weight-loss drug news with some bullish commentary and said the company has become an attractive takeover target.",
            "banner_image": "https://images.mktw.net/im-520633/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.145905,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.186378",
                    "ticker_sentiment_score": "0.071138",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "0.298538",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.164638",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss - Eli Lilly and Co  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37367547/large-us-drug-makers-highlight-indian-market-for-their-blockbuster-drugs-including-for-weight-los",
            "time_published": "20240228T154650",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY CEO, David Ricks, shared the pharmaceutical giant's plans to introduce its obesity drug, tirzepatide, in India as early as next year. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss in the United States, holds promise for the Indian market.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ardelyx-ARDX_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.16621,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.265542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.270523",
                    "ticker_sentiment_score": "0.259582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.204647",
                    "ticker_sentiment_score": "-0.017752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Weight Loss Drug Targets Ozempic And Mounjaro Makers' Supremacy - What To Know",
            "url": "https://www.forbes.com/sites/roberthart/2024/02/28/viking-weight-loss-drug-targets-ozempic-and-mounjaro-makers-supremacy---what-to-know/",
            "time_published": "20240228T151105",
            "authors": [
                "Robert Hart"
            ],
            "summary": "U.S. biotech Viking Therapeutics marked itself as a serious competitor in the growing weight loss drug market this week after revealing promising data suggesting its therapy rivals-and outperforms-blockbusters from industry giants Novo Nordisk and Eli Lilly, which dominate the diabetes and ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65df4c6fa9185c9f89605cd4/0x0.jpg?format=jpg&crop=3167,1780,x0,y89,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.062542,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "0.191143",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "-0.012997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.147818",
                    "ticker_sentiment_score": "0.131942",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Novo Nordisk  ( NVO )  is a Strong Momentum Stock",
            "url": "https://www.zacks.com/stock/news/2233251/heres-why-novo-nordisk-nvo-is-a-strong-momentum-stock",
            "time_published": "20240228T145011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.387146,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.406526",
                    "ticker_sentiment_score": "0.262944",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The pet drugs vets are now prescribing look a lot more like human medications",
            "url": "https://www.cnbc.com/2024/02/28/new-pet-drugs-are-looking-a-lot-more-like-human-medications.html",
            "time_published": "20240228T133848",
            "authors": [
                "Ian Thomas"
            ],
            "summary": "New drug treatment options are coming for cats and dogs as the divide between animal and human health is starting to narrow.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107372982-17078438181707843816-33319440180-1080pnbcnews.jpg?v=1707843818&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.090748,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.326884",
                    "ticker_sentiment_score": "0.073785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.104308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.104308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.111834",
                    "ticker_sentiment_score": "0.102873",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Miracle Or Myth? Survey Shows Americans Doubt Ozempic, Wegovy's Weight Loss Claims - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/02/37362440/miracle-or-myth-survey-shows-americans-doubt-ozempic-wegovys-weight-loss-claims",
            "time_published": "20240228T133147",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "A recent study by the Pew Research Center has shown that a majority of Americans are doubtful about the potential of new weight loss drugs, such as Ozempic and Wegovy, to impact the country's obesity rate significantly.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-Insulin-Injection-Pen-Or-Insulin.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.145437,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.244109",
                    "ticker_sentiment_score": "0.141337",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows - Vivani Medical  ( NASDAQ:VANI ) ",
            "url": "https://www.benzinga.com/news/24/02/37361308/exclusive-vivani-medical-says-weight-lossdiabetes-implant-at-par-with-novo-nordisks-famed-injectable",
            "time_published": "20240228T130013",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Wednesday, Vivani Medical Inc VANI released preclinical data on weight loss effects for NPM-115, the company's miniature, twice-yearly exenatide subdermal implant under development for chronic weight management.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-Photo-by-Vidmir-Rais-via-Pix_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.026045,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.204936",
                    "ticker_sentiment_score": "-0.140137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.204936",
                    "ticker_sentiment_score": "0.026444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VANI",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.104394",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly's revolutionary obesity pill to hit Indian market by 2025, says CEO David Ricks",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/eli-lillys-revolutionary-obesity-pill-to-hit-indian-market-by-2025-says-ceo-david-ricks-bkg/3408068/",
            "time_published": "20240228T102840",
            "authors": [
                "Breaking News Desk"
            ],
            "summary": "Eli Lilly CEO David Ricks recently said that the pharma major is looking to introduce its obesity medication tirzepatide in the Indian market as early as next year, a Reuters report said on Wednesday.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/02/FE_c9d43e.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.337913,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.230601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly expects to launch obesity drug in India next year, says CEO | Company News",
            "url": "https://www.business-standard.com/companies/news/eli-lilly-expects-to-launch-obesity-drug-in-india-next-year-says-ceo-124022800389_1.html",
            "time_published": "20240228T074854",
            "authors": [
                "Reuters"
            ],
            "summary": "Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters Eli Lilly expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2020-10/14/full/1602650848-4332.jpg?im=FitAndFill=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.259735,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.334008",
                    "ticker_sentiment_score": "0.406141",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly CEO David Ricks says its obesity drug could enter India as early as 2025",
            "url": "https://www.moneycontrol.com/news/business/eli-lilly-ceo-david-ricks-says-its-obesity-drug-could-enter-india-as-early-as-2025-12369691.html",
            "time_published": "20240228T065840",
            "authors": [],
            "summary": "Eli Lilly's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/06/eli-lilly-bbo-770x433.jpg",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.27986,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.363388",
                    "ticker_sentiment_score": "0.42933",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk and Eli Lilly Stocks Slipped Today",
            "url": "https://www.fool.com/investing/2024/02/27/why-novo-nordisk-and-eli-lilly-stocks-slipped-toda/",
            "time_published": "20240227T230100",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767102/medical-professional-with-hand-on-head.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.065764,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.572601",
                    "ticker_sentiment_score": "0.031781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.249106",
                    "ticker_sentiment_score": "0.005675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47452",
                    "ticker_sentiment_score": "0.028501",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Today: Stocks End Mixed After Disappointing Economic Data",
            "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-end-mixed-after-disappointing-economic-data",
            "time_published": "20240227T210737",
            "authors": [
                "Karee Venema"
            ],
            "summary": "Tuesday marked another choppy day for stocks as investors looked ahead to this week's key inflation update and the impact it may or may not have on the Fed's plans for interest rates.",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/hbRMDVRhfJobMQLXddLEdj-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": -0.004874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.061894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.079591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.107479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.061894",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Splits: Should You Buy?",
            "url": "https://www.zacks.com/commentary/2232674/stock-splits-should-you-buy",
            "time_published": "20240227T202200",
            "authors": [
                "Derek Lewis"
            ],
            "summary": "A retail giant has recently undergone a split, hoping to make shares more accessible. But is buying post-split a viable strategy?",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/23/2523.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.317414,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.362858",
                    "ticker_sentiment_score": "0.346458",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362858",
                    "ticker_sentiment_score": "0.335221",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.490988",
                    "ticker_sentiment_score": "0.437086",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics soars 104% after its GLP-1 weight-loss drug posts impressive results in Phase 2 trial",
            "url": "https://markets.businessinsider.com/news/stocks/viking-therapeutics-stock-price-double-glp-1-weight-loss-drug-2024-2",
            "time_published": "20240227T185200",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Viking Therapeutics Stock Price Doubles After GLP-1 Weight-Loss Drug Shines - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.041082,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.334008",
                    "ticker_sentiment_score": "0.125484",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.253866",
                    "ticker_sentiment_score": "0.094851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.12103",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Healthy Returns: The newest treatment use for weight loss drugs? Liver disease",
            "url": "https://www.cnbc.com/2024/02/27/healthy-returns-liver-disease-is-newest-weight-loss-drug-use-.html",
            "time_published": "20240227T175904",
            "authors": [
                "Annika Kim Constantino",
                "Ashley Capoot"
            ],
            "summary": "Zealand Pharma, Eli Lilly show the potential of treating liver disease with weight loss drugs, while the Change Healthcare outage continues after a cyberattack.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/104796249-Liver.JPG?v=1709056251&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.033894",
                    "ticker_sentiment_score": "0.135614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.033894",
                    "ticker_sentiment_score": "-0.25426",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067727",
                    "ticker_sentiment_score": "0.009058",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.101439",
                    "ticker_sentiment_score": "-0.11362",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet the 'Granolas,' Europe's answer to the Magnificent 7 stocks | Business",
            "url": "https://www.cnn.com/2024/02/27/investing/granolas-europe-stocks-magnificent-7/index.html",
            "time_published": "20240227T165700",
            "authors": [
                "Anna Cooban"
            ],
            "summary": "Meet the 'Granolas,' Europe's answer to the Magnificent 7 stocks ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-2032875265.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995015"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.29058,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "-0.071969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.086838",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.172919",
                    "ticker_sentiment_score": "0.176351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.371552",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "-0.071969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "-0.071969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "-0.071969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results",
            "url": "https://www.investors.com/news/technology/viking-therapeutics-skyrockets-on-weight-loss-drug-trial-results/",
            "time_published": "20240227T125800",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Viking Therapeutics ( VKTX ) said Tuesday that its weight-loss drug achieved all goals of its phase two study. Viking stock more than doubled in premarket trade. Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , which already have weight-loss drugs on the market, fell modestly.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/12/Stock-biotech-12-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.026041,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "-0.217522",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.617765",
                    "ticker_sentiment_score": "-0.170661",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "-0.217522",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Viking Therapeutics' stock doubles after company reports positive results in trial of weight-loss drug",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767",
            "time_published": "20240227T122200",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Investors cheer what may be a cheap way to play the current weight-loss drug mania.",
            "banner_image": "https://images.mktw.net/im-832731/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.070779,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.317254",
                    "ticker_sentiment_score": "0.12217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.02259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.193723",
                    "ticker_sentiment_score": "0.173518",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Drugs like Ozempic and Wegovy could strengthen the US economy, Goldman Sachs predicts | Business",
            "url": "https://www.cnn.com/2024/02/27/business/weight-loss-drugs-ozempic-us-economy-goldman-sachs/index.html",
            "time_published": "20240227T120000",
            "authors": [
                "Bryan Mena"
            ],
            "summary": "Drugs like Ozempic and Wegovy could strengthen the US economy, Goldman Sachs predicts ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1807239973.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.070273,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "-0.063504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.055881",
                    "ticker_sentiment_score": "-0.04403",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.166551",
                    "ticker_sentiment_score": "0.016833",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons",
            "url": "https://www.cnbc.com/2024/02/26/granolas-stocks-power-europe-to-record-highs-drawing-magnificent-7-comparisons.html",
            "time_published": "20240227T085438",
            "authors": [
                "Elliot Smith"
            ],
            "summary": "Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107378746-17090209321709020930-33496786937-1080pnbcnews.jpg?v=1709020932&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999355"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.12762,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.222347",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons",
            "url": "https://www.cnbc.com/2024/02/27/granolas-stocks-power-europe-to-record-highs-drawing-magnificent-7-comparisons.html",
            "time_published": "20240227T061249",
            "authors": [
                "Elliot Smith"
            ],
            "summary": "Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107378125-1708948204629-1708946815-33485900583-hd.jpg?v=1708948204&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999355"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.12762,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.222347",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "-0.061131",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Soros Fund 13F Filing Provides Insight Into Which Stocks To Invest In",
            "url": "https://www.benzinga.com/general/24/02/37319582/soros-fund-13f-filing-provides-insight-into-which-stocks-to-invest-in",
            "time_published": "20240226T193310",
            "authors": [
                "Chris Bibey"
            ],
            "summary": "George Soros is best known as one of the most successful investors the world has ever seen. With this, he's grown Soros Fund Management to $7.6 billion in assets under management. Soros has a net worth of roughly $6.7 billion and for 30 years managed the Quantum Fund, which had an average annual ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/George-Soros.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999967"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.318117,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.157141",
                    "ticker_sentiment_score": "0.181426",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPLK",
                    "relevance_score": "0.208464",
                    "ticker_sentiment_score": "0.323724",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.190674",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CHTR",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LBRDP",
                    "relevance_score": "0.157141",
                    "ticker_sentiment_score": "0.144389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.157141",
                    "ticker_sentiment_score": "0.067816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:GBP",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.120609",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs - Amgen  ( NASDAQ:AMGN ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g",
            "time_published": "20240226T182533",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Amgen Inc AMGN is expected to unveil updates on various programs this year, targeting significant markets. Despite concerns about the company's long-term growth amid exclusivity losses, Goldman Sachs notes that Amgen ( Buy rating, $350 price target ) is seen as well-positioned to capitalize on ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Autoinjector-with-Amgevita-by-Amgen-Adal.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.137255,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.371523",
                    "ticker_sentiment_score": "0.172847",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.454714",
                    "ticker_sentiment_score": "0.333285",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.082069",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases",
            "url": "https://www.prnewswire.com/news-releases/neomorph-announces-multi-target-collaboration-with-novo-nordisk-to-discover-novel-molecular-glue-degraders-for-cardiometabolic-and-rare-diseases-302070208.html",
            "time_published": "20240226T170600",
            "authors": [
                "Neomorph"
            ],
            "summary": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2341384/Neomorph_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142894,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.400052",
                    "ticker_sentiment_score": "0.183584",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases",
            "url": "https://www.prnewswire.com/news-releases/neomorph-announces-multi-target-collaboration-with-novo-nordisk-to-discover-novel-molecular-glue-degraders-for-cardiometabolic-and-rare-diseases-302070201.html",
            "time_published": "20240226T170600",
            "authors": [
                "Neomorph"
            ],
            "summary": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2341384/Neomorph_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142894,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.400052",
                    "ticker_sentiment_score": "0.183584",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases",
            "url": "https://www.newswire.ca/news-releases/neomorph-announces-multi-target-collaboration-with-novo-nordisk-to-discover-novel-molecular-glue-degraders-for-cardiometabolic-and-rare-diseases-808682409.html",
            "time_published": "20240226T170600",
            "authors": [
                "Neomorph"
            ],
            "summary": "Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for ... Canada ...",
            "banner_image": "https://mma.prnewswire.com/media/2341384/Neomorph_Logo.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142894,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.400052",
                    "ticker_sentiment_score": "0.183584",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors - AstraZeneca  ( NASDAQ:AZN ) , Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/37315592/eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors",
            "time_published": "20240226T163135",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company's shares 30% higher.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.182634,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.5341",
                    "ticker_sentiment_score": "0.262817",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "-0.009696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.072593",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "0.059846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.165031",
                    "ticker_sentiment_score": "-0.009696",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biotech Stocks In A Tizzy As New Weight-Loss Rival Enters The Arena",
            "url": "https://www.investors.com/news/technology/biotech-stocks-diverge-on-new-results-for-weight-loss-drug-in-mash-patients/",
            "time_published": "20240226T155200",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Altimmune-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.170267,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.472711",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.059975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.282886",
                    "ticker_sentiment_score": "0.059661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.013949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "-0.030348",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Presenting The 2024 Oscars Of Healthcare Innovation",
            "url": "https://www.forbes.com/sites/joeharpaz/2024/02/26/presenting-the-2024-oscars-of-healthcare-innovation/",
            "time_published": "20240226T140000",
            "authors": [
                "Joe Harpaz"
            ],
            "summary": "The star-studded award shows with glitzy outfits and legions of paparazzi may feel foreign to the world of healthcare policy and tech innovation, but I see several storylines in my field that feature Hollywood-esque drama around them.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65d8c822984a6ed4eab7c2d2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.23626,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050359",
                    "ticker_sentiment_score": "0.144867",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: Carrols, Nextracker, Costco in Focus",
            "url": "https://www.zacks.com/stock/news/2231450/take-the-zacks-approach-to-beat-the-market-carrols-nextracker-costco-in-focus",
            "time_published": "20240226T132500",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a0/810.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.231573,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.123621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.107965",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.1013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.089248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRCX",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.089248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HTHT",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.205792",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TAST",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.313029",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICE",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.060311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFM",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.124412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.060311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WT",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.135472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.034087",
                    "ticker_sentiment_score": "0.198846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.034087",
                    "ticker_sentiment_score": "0.198846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Warren Buffett's Berkshire Is On Cusp Of Joining The $1 Trillion Club",
            "url": "https://www.investors.com/news/warren-buffett-stock-berkshire-hathaway-on-cusp-of-1-trillion-market-cap/",
            "time_published": "20240226T123000",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "The trillion-dollar club is largely the preserve of tech titans such as Apple ( AAPL ) and Nvidia ( NVDA ) , with Meta Platforms ( META ) rejoining that level this year. But Warren Buffett's Berkshire Hathaway ( BRKB ) is knocking on the door. Berkshire Hathaway has a $952.75 billion ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/05/stock-Buffett-Warren-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.087538,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.034126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.034596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.081763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.078441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.130867",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.034126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.449219",
                    "ticker_sentiment_score": "0.224219",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "-0.145508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "-0.479514",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.060578",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.329992",
                    "ticker_sentiment_score": "0.15192",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/02/26/2834952/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240226T110200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 26 February 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.12545,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.045583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.200514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk and Eli Lilly rival soars 30% after promising weight-loss drug results",
            "url": "https://www.cnbc.com/2024/02/26/novo-nordisk-and-eli-lilly-rival-soars-26percent-after-promising-test-results.html",
            "time_published": "20240226T103034",
            "authors": [
                "Jenni Reid"
            ],
            "summary": "Zealand Pharma's Phase 2 trial was an \"uniquivocal win\" for a drug that can treat both liver disease and obesity, analysts said.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107366836-17066941841706694181-33131569394-1080pnbcnews.jpg?v=1706694183&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.199786,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.158516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.158516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's how I see the Fed's rate-cut dilemma playing out - and 5 more themes for 2024",
            "url": "https://www.cnbc.com/2024/02/25/jim-cramer-heres-how-i-see-the-feds-rate-cut-dilemma-playing-out.html",
            "time_published": "20240225T190101",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "During the CNBC Investing Club's second Annual Meeting on Saturday, Jim Cramer said the U.S. economy may remain too strong for the Fed to cut rate this year.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107377956-7ED4-CramerMeeting-022424-Part1.jpg?v=1708813527&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999174"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.109233,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IR",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PWR",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WYNN",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRA",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NUE",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.044496",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT",
            "url": "https://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-encourages-altimmune-inc-investors-to-inquire-about-securities-class-action-investigation--alt-302070382.html",
            "time_published": "20240225T183000",
            "authors": [
                "THE ROSEN LAW FIRM",
                "P. A."
            ],
            "summary": "ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.178351,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.49637",
                    "ticker_sentiment_score": "0.15497",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "-0.036123",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT - Altimmune  ( NASDAQ:ALT ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37301304/rosen-a-leading-investor-rights-law-firm-encourages-altimmune-inc-investors-to-inquire-about-secur",
            "time_published": "20240224T181500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Feb. 24, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Altimmune, Inc.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.135567,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.449219",
                    "ticker_sentiment_score": "0.14256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "-0.034518",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Ginkgo Bioworks Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2024/02/24/is-ginkgo-bioworks-stock-a-buy-now/",
            "time_published": "20240224T133000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Ginkgo Bioworks says it is experiencing strong growth from its biopharma customers.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765979/people-working-in-a-lab.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.202434,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DNA",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "0.330503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.068785",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.068785",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Wall Street Analyst Thinks Novo Nordisk Stock Is Going to $140. Is It a Buy?",
            "url": "https://www.fool.com/investing/2024/02/24/1-wall-street-analyst-thinks-novo-nordisk-stock-is/",
            "time_published": "20240224T121000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "There's little reason to think that a big correction is in store.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766297/two-investors-consider-a-stock-with-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.11706,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.412298",
                    "ticker_sentiment_score": "0.254144",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Protein Labeling Global Market Report 2024, by Product  ( Reagents; Protein; Enzymes; Probes/ Tags; Monoclonal Antibodies ) , by Labeling Method and by Application",
            "url": "https://www.prnewswire.com/news-releases/protein-labeling-global-market-report-2024-by-product-reagents-protein-enzymes-probes-tags-monoclonal-antibodies-by-labeling-method-and-by-application-302069750.html",
            "time_published": "20240223T181500",
            "authors": [
                "Research and Markets"
            ],
            "summary": "Protein Labeling Global Market Report 2024, by Product ( Reagents. Protein. Enzymes. Probes/ Tags. Monoclonal ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.26683,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.104863",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The more Americans that take Ozempic, the faster the US economy will grow, Goldman Sachs says",
            "url": "https://www.businessinsider.com/us-economy-faster-growth-ozempic-glp-1-weight-loss-drugs-2024-2",
            "time_published": "20240223T152200",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "More Americans taking Ozempic will boost US economy growth outlook - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.068238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.249106",
                    "ticker_sentiment_score": "-0.056774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.172186",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio",
            "url": "https://www.zacks.com/stock/news/2230895/why-this-1-medical-stock-could-be-a-great-addition-to-your-portfolio",
            "time_published": "20240223T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99489"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": 0.33556,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.190167",
                    "ticker_sentiment_score": "0.217116",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37284940/obesity-solutions-like-weight-loss-drugs-to-act-as-catalyst-for-economic-surge-goldman-sachs-fore",
            "time_published": "20240223T142424",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Goldman Sachs economists foresee a potential 1% boost to the United States' Gross Domestic Product ( GDP ) in the coming years, attributing this surge to the widespread use of weight-loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.275147,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.380978",
                    "ticker_sentiment_score": "0.315018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.152041",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "There's A Problem With Today's Obesity Drugs - How These Companies Are Solving It",
            "url": "https://www.investors.com/news/technology/weight-loss-drugs-how-outliers-like-biohaven-regeneron-are-trying-to-squeeze-into-the-obesity-space/",
            "time_published": "20240223T133000",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/A1MAIN_weightloss_022324.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.012175,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.027602",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.063933",
                    "ticker_sentiment_score": "-0.03917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARWR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.015999",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALUR",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.05222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.09668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.061293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.158938",
                    "ticker_sentiment_score": "0.096962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.092157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "-0.025591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.031992",
                    "ticker_sentiment_score": "0.092157",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street",
            "url": "https://www.fool.com/investing/2024/02/23/1-beaten-down-stock-that-could-soar-by-40-accordin/",
            "time_published": "20240223T104300",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The company might have a bright future, but is now the right time to buy shares?",
            "banner_image": "https://media.ycharts.com/charts/ff4c0402fd4380f9ded0ead7abb69c1d.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.159353,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.597357",
                    "ticker_sentiment_score": "0.26683",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "0.144794",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value",
            "url": "https://www.fool.com/investing/2024/02/23/2-top-biotech-stocks-that-wall-street-thinks-could/",
            "time_published": "20240223T075900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "These two businesses have viable paths to making investors richer -- possibly soon.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766030/scientist-looks-into-microscope-while-sitting-at-bench-in-laboratory.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.221744,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IOVA",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "-0.206456",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "0.071018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04882",
                    "ticker_sentiment_score": "0.022897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.04882",
                    "ticker_sentiment_score": "0.022897",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease - Eli Lilly  ( NYSE:LLY ) , Better Therapeutics  ( NASDAQ:BTTX ) ",
            "url": "https://www.benzinga.com/partner/biotech/24/02/37268309/better-therapeutics-follows-up-wins-including-fda-authorization-for-aspyrerx-in-2023-with-securin",
            "time_published": "20240222T182518",
            "authors": [
                "Faith Ashmore"
            ],
            "summary": "Researchers, scientists and practitioners in the past few decades have begun to look at healthcare from a more holistic perspective, often challenging traditional medicine. The question on the minds of many is how to integrate holistic medicine into American healthcare - at scale.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Screenshot-2024-02-22-at-11-51-01-PM.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.282137,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.208398",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BTTX",
                    "relevance_score": "0.46898",
                    "ticker_sentiment_score": "0.421072",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110717",
                    "ticker_sentiment_score": "0.208398",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37262905/global-access-to-weight-loss-treatments-indian-pharma-giants-eye-affordable-wegovy-alternatives-a",
            "time_published": "20240222T150154",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "While Novo Nordisk A/S NVO faces challenges in meeting the global demand for its highly sought-after weight-loss treatment, Wegovy, Indian drugmakers see an opportunity to enhance global access and affordability.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.117775,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.175991",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.",
            "url": "https://www.fool.com/investing/2024/02/22/1-pharmaceutical-stock-that-looks-unstoppable/",
            "time_published": "20240222T120000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765806%2Fnurse-checking-elderly-patients-blood-pressure-long-term-care-senior-nursing-home-poc.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.307091,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.6979",
                    "ticker_sentiment_score": "0.507042",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "0.131827",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Indian pharma cos make versions of Wegovy to get in on weight-loss windfall | News",
            "url": "https://www.business-standard.com/industry/news/indian-pharma-cos-make-versions-of-wegovy-to-get-in-on-weight-loss-windfall-124022200319_1.html",
            "time_published": "20240222T070219",
            "authors": [
                "Reuters"
            ],
            "summary": "Indian pharma cos make versions of Wegovy to get in on weight-loss windfall Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-09/05/full/1693933453-2949.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.021607,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "-0.042068",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "India pharma companies develop versions of Wegovy to get in on weight-loss windfall",
            "url": "https://www.moneycontrol.com/news/business/economy/india-pharma-companies-develop-versions-of-wegovy-to-get-in-on-weight-loss-windfall-12329251.html",
            "time_published": "20240222T062114",
            "authors": [],
            "summary": "With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/02/Kejriwal.png?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Economy",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004809,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "-0.042165",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 No-Brainer Biotech Stocks to Buy Right Now",
            "url": "https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/",
            "time_published": "20240221T150000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These stocks are used to beating the market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765481/doctor-and-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.291631,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "REGN",
                    "relevance_score": "0.103331",
                    "ticker_sentiment_score": "0.349258",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.441059",
                    "ticker_sentiment_score": "0.455772",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.103331",
                    "ticker_sentiment_score": "0.091526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.055634",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing - Conagra Brands  ( NYSE:CAG ) ",
            "url": "https://www.benzinga.com/news/large-cap/24/02/37237352/weight-loss-drugs-vs-conagra-foods-company-optimistic-amid-shifting-consumer-demands-influenced-by",
            "time_published": "20240221T145400",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "At the Consumer Analyst Group of New York Conference in Boca Raton, Florida, Conagra Brands Inc CAG Executive Tom McGough addressed concerns about potential sales declines for U.S. food companies due to the increased use of weight-loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Indianapolis---Circa-July-2019-Conagra-B.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.085931,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CAG",
                    "relevance_score": "0.429845",
                    "ticker_sentiment_score": "0.043073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GIS",
                    "relevance_score": "0.223522",
                    "ticker_sentiment_score": "0.14054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.150122",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150122",
                    "ticker_sentiment_score": "-0.329993",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.150122",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  is a Top Growth Stock for the Long-Term",
            "url": "https://www.zacks.com/stock/news/2229330/why-novo-nordisk-nvo-is-a-top-growth-stock-for-the-long-term",
            "time_published": "20240221T144511",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default260.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": 0.405079,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.409778",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Notice for the Annual General Meeting of Novo Nordisk A/S",
            "url": "https://www.globenewswire.com/news-release/2024/02/21/2832822/0/en/Notice-for-the-Annual-General-Meeting-of-Novo-Nordisk-A-S.html",
            "time_published": "20240221T140300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 21 February 2024 - The Annual General Meeting of Novo Nordisk A/S will be held on: ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.054272,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.126119",
                    "ticker_sentiment_score": "0.04594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.126119",
                    "ticker_sentiment_score": "0.04594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.572601",
                    "ticker_sentiment_score": "0.100071",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Has More Than an Ozempic Competitor -- Much More",
            "url": "https://www.fool.com/investing/2024/02/21/eli-lilly-has-more-than-an-ozempic-competitor-much/",
            "time_published": "20240221T113900",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly's hottest treatment might be Mounjaro, but the company has a lot more at its disposal.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765536%2Fdoctors-office-checkup-patient-hospital.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.220724,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.467176",
                    "ticker_sentiment_score": "0.300582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TFC",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "-0.05942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.147153",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT - Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37222782/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-catalent-inc-ct",
            "time_published": "20240220T211507",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( \"Catalent\" or the \"Company\" ) CTLT. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.069793,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.612521",
                    "ticker_sentiment_score": "0.13523",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.130874",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData",
            "url": "https://www.investorideas.com/news/2024/biotech/02201Global-Biopharmaceutical.asp",
            "time_published": "20240220T150551",
            "authors": [],
            "summary": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals ... ...",
            "banner_image": null,
            "source": "Investor Ideas",
            "category_within_source": "n/a",
            "source_domain": "www.investorideas.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.152626,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "0.108103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "-0.036799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "0.010941",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.260895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "-0.175762",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "-0.175762",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.208134",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.260895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.208134",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "-0.069573",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - Share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/02/19/2831299/0/en/Novo-Nordisk-A-S-Share-repurchase-programme.html",
            "time_published": "20240219T142900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 19 February 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.127925,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.800656",
                    "ticker_sentiment_score": "0.20564",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.",
            "url": "https://www.fool.com/investing/2024/02/18/novo-nordisk-has-more-than-ozempic-one-of-its/",
            "time_published": "20240218T143000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too.",
            "banner_image": "https://media.ycharts.com/charts/1ed14a2a1bf47b44b31b4ba079332fb3.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.217474,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "0.050831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "0.050831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "0.096448",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.595343",
                    "ticker_sentiment_score": "0.362101",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "0.050831",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Where Will Eli Lilly Be in 5 Years?",
            "url": "https://www.fool.com/investing/2024/02/18/where-will-eli-lilly-be-in-5-years/",
            "time_published": "20240218T064500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The stock will still be crushing the market in all likelihood.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765320/patient-taking-medicine.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.252692,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.377958",
                    "ticker_sentiment_score": "0.149182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.086016",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Great Business Podcasts For Business Leaders And Builders",
            "url": "https://www.forbes.com/sites/juliettehan/2024/02/17/3-great-business-podcasts-for-business-leaders-and-builders/",
            "time_published": "20240217T214129",
            "authors": [
                "Juliette Han",
                "PhD"
            ],
            "summary": "Many top business podcasts focus on how to start a company, an entrepreneurship journey, or a successful founder ( sometimes billionaire ) story. Unsurprisingly, personal stories of challenges and growth are compelling, especially for aspiring entrepreneurs.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65d126c3c3ca996679826dd3/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.234234,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NKE",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.06573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.06573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.06573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.032395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.06573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.06573",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT",
            "url": "https://www.prnewswire.com/news-releases/rosen-leading-investor-counsel-encourages-altimmune-inc-investors-to-inquire-about-securities-class-action-investigation--alt-302064336.html",
            "time_published": "20240216T213300",
            "authors": [
                "P. A.",
                "THE ROSEN LAW FIRM"
            ],
            "summary": "ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.178351,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.49637",
                    "ticker_sentiment_score": "0.15497",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "-0.036123",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bubble talk builds in frothy US stocks",
            "url": "https://www.ft.com/content/87395804-37ba-40e0-bc4b-61caa2eeb781",
            "time_published": "20240216T200033",
            "authors": [
                "Katie Martin"
            ],
            "summary": "The surge in shares such as Nvidia spark concerns over 'irrational exuberance' ...",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fpublic.flourish.studio%2Fvisualisation%2F16829717%2Fthumbnail?source=next-article&fit=scale-down&quality=highest&width=1020&dpr=1",
            "source": "Financial Times",
            "category_within_source": "Markets",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.004919,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.021219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.016311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "-0.016871",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "0.025719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.044801",
                    "ticker_sentiment_score": "-0.016724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prothena  ( PRTA )  Q4 Earnings Miss Estimates on Higher R&D Expense",
            "url": "https://www.zacks.com/stock/news/2227547/prothena-prta-q4-earnings-miss-estimates-on-higher-rd-expense",
            "time_published": "20240216T183300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.016577,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "0.017961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.55533",
                    "ticker_sentiment_score": "0.060912",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.389636",
                    "ticker_sentiment_score": "0.081716",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What you need to know about health insurance coverage for new weight loss drugs, and how to save on costs",
            "url": "https://www.cnbc.com/2024/02/16/what-you-need-to-know-about-health-coverage-for-new-weight-loss-drugs.html",
            "time_published": "20240216T154911",
            "authors": [
                "Cheryl Winokur Munk"
            ],
            "summary": "Weight loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound cost over $1,000 a month, and right now, most employer health insurance doesn't cover it.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107366098-17065763711706576369-33112052331-1080pnbcnews.jpg?v=1706576370&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.119174,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.025845",
                    "ticker_sentiment_score": "0.1067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.103109",
                    "ticker_sentiment_score": "0.044869",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 major employers said they stopped paying for weight-loss drugs like Wegovy after the drugmaker threatened to penalize them",
            "url": "https://www.businessinsider.com/wegovy-maker-novo-nordisk-employers-weight-loss-drugs-restrictions-coverage-2024-2",
            "time_published": "20240216T144700",
            "authors": [
                "Shelby Livingston"
            ],
            "summary": "Wegovy maker dinged employers for restricting hot weight-loss drugs - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.045892,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "-0.009078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.074233",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024 | Business",
            "url": "https://www.cnn.com/2024/02/15/economy/ozempic-mounjaro-drug-prices-increase/index.html",
            "time_published": "20240215T163500",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "Ozempic, Mounjaro and hundreds of other drugs become even more expensive in ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/marlene-foss.jpeg?c=16x9",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.077074,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.063008",
                    "ticker_sentiment_score": "0.075346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.063315",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On Eli Lilly Stock Thursday? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37160096/uk-becomes-first-major-market-for-eli-lillys-mounjaro-prefilled-pen-for-tackling-obesity",
            "time_published": "20240215T150938",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Pharmaceutical giant Eli Lilly And Co LLY is set to launch its highly-anticipated obesity drug, Mounjaro ( tirzepatide ) , in Britain this week, making the U.K. the fourth European country to introduce the famed medication.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Basra--Iraq---July-9--2023-Photo-Of-Moun.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.187575,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.280615",
                    "ticker_sentiment_score": "0.121513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.012856",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Vanguard Fund I Plan On Buying Hand Over Fist This Year",
            "url": "https://www.fool.com/investing/2024/02/15/1-vanguard-fund-i-plan-on-buying-hand-over-fist-th/",
            "time_published": "20240215T141500",
            "authors": [
                "George Budwell"
            ],
            "summary": "This small-cap fund could benefit enormously from a major catalyst later this year.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765297%2Ftime-to-buy.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996718"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.230532,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.251986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.251986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BLDR",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.052001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy",
            "time_published": "20240215T140535",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) . The update comes when the Danish drugmaker is already struggling to meet the demand from adult patients.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.030964,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.201435",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:KMD",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.15199",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How to access the new weight loss drugs",
            "url": "https://www.cnn.com/2024/02/15/health/weight-loss-drugs-access-business-wellness/index.html",
            "time_published": "20240215T124500",
            "authors": [
                "Andrea Kane"
            ],
            "summary": "Getting your hands on the new weight loss meds isn't simple. Here are 5 things to know ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230615163958-meg-tirrell.jpg?c=16x9",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.048294,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.036037",
                    "ticker_sentiment_score": "-0.011572",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.209407",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.004065",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Magnificent Growth Stocks to Buy With $500",
            "url": "https://www.fool.com/investing/2024/02/15/2-magnificent-growth-stocks-to-buy-with-500/",
            "time_published": "20240215T124500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "No need to break the bank to invest in promising stocks.",
            "banner_image": "https://media.ycharts.com/charts/9af8b50ffc1788153770b1ac93b6cb06.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.248864,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VEEV",
                    "relevance_score": "0.297301",
                    "ticker_sentiment_score": "0.058483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.060848",
                    "ticker_sentiment_score": "0.056101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.239895",
                    "ticker_sentiment_score": "0.192579",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060848",
                    "ticker_sentiment_score": "0.056101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.060848",
                    "ticker_sentiment_score": "0.056101",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024",
            "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2023-and-provides-financial-expectations-for-2024-302062983.html",
            "time_published": "20240215T120000",
            "authors": [
                "Alkermes plc"
            ],
            "summary": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                }
            ],
            "overall_sentiment_score": 0.16266,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MURA",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALKS",
                    "relevance_score": "0.343175",
                    "ticker_sentiment_score": "0.036906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.006869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.155303",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "-0.02066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "-0.02066",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Unusual Options Activity For February 14 - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/37136438/novo-nordisk-unusual-options-activity-for-february-14",
            "time_published": "20240214T193102",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.090114,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.097062",
                    "ticker_sentiment_score": "-0.197985",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.727604",
                    "ticker_sentiment_score": "0.264417",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year",
            "url": "https://www.fool.com/investing/2024/02/14/1-potential-catalyst-that-could-light-a-fire-under/",
            "time_published": "20240214T133000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Don't let the stock's high price deceive you -- Novo Nordisk can still make for a great investment.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764833/a-doctor-looking-at-a-tablet-with-another-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.181462,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.135035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.462743",
                    "ticker_sentiment_score": "0.223383",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "-0.035182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "-0.035182",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?",
            "url": "https://www.fool.com/investing/2024/02/14/amgen-takes-aim-at-novo-nordisk-and-eli-lilly-but/",
            "time_published": "20240214T075900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It faces both clinical and competitive barriers, but they might not matter.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764673/lab-worker-women-in-stem-science-research.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.190769,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.185662",
                    "ticker_sentiment_score": "0.188728",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.230892",
                    "ticker_sentiment_score": "0.215529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.046816",
                    "ticker_sentiment_score": "0.062609",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.230892",
                    "ticker_sentiment_score": "0.185687",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/news/24/02/37101437/heres-how-much-you-would-have-made-owning-novo-nordisk-stock-in-the-last-10-years",
            "time_published": "20240213T180033",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.03% on an annualized basis producing an average annual return of 18.43%. Currently, Novo Nordisk has a market capitalization of $533.94 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday",
            "url": "https://www.cnbc.com/2024/02/13/why-we-would-be-considering-buying-more-eli-lilly-shares-if-they-were-down.html",
            "time_published": "20240213T171555",
            "authors": [
                "Morgan Chittum"
            ],
            "summary": "The Investing Club holds its \"Morning Meeting\" every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107372911-17078386721707838668-33318611669-1080pnbcnews.jpg?v=1707838672&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.306676,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.216215",
                    "ticker_sentiment_score": "0.223262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "0.134232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "0.134232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.169681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Meet America's Best Large Employers 2024",
            "url": "https://www.forbes.com/sites/rachelpeachman/2024/02/13/meet-americas-best-large-employers-2024/",
            "time_published": "20240213T144845",
            "authors": [
                "Rachel Rabkin Peachman"
            ],
            "summary": "It began with Taylor Swift's \"Anti-Hero\" blasting through the loudspeakers at Children's Hospital Colorado. Then came the staffers, dressed as cheerleaders, superheroes, witches and Disney characters, who bounded to the center of the hospital's sun-filled multi-level atrium.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ca44cb74559b95a2f6d153/0x0.jpg?format=jpg&crop=4979,3318,x466,y321,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.275671,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GRMN",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.084091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.084091",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/house-select-committee-tours-ginkgo-bioworks-previews-biofab1-ginkgos-new-integrated-data-generation-facility-set-to-launch-in-2025-302060620.html",
            "time_published": "20240213T120100",
            "authors": [],
            "summary": "House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.229441,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.137844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTVA",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.129848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.252332",
                    "ticker_sentiment_score": "0.237875",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.129848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.129848",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSUMF",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.129848",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.",
            "url": "https://www.fool.com/investing/2024/02/13/move-aside-eli-lilly-and-novo-nordisk-wall-street/",
            "time_published": "20240213T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "There's more for investors to get excited about in the biopharma world than just weight-loss drugs.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764848/scientists-happy.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.29916,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.488445",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.479945",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.472338",
                    "ticker_sentiment_score": "0.427854",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "ZTS: Zoetis  ( ZTS ) : Analyzing Earnings for Potential Gains",
            "url": "https://stocknews.com/news/zts-gsk-abbv-nvo-zoetis-zts-analyzing-earnings-for-potential-gains/",
            "time_published": "20240212T174911",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "Zoetis Inc. ( ZTS ) is a leading force in the realm of animal health, specializing in the discovery, development, manufacturing, and global distribution of vital medicines, vaccines, and diagnostic tools.",
            "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999941"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.306689,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.738815",
                    "ticker_sentiment_score": "0.45306",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.064079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.064079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.089462",
                    "ticker_sentiment_score": "0.064079",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37074665/novo-nordisks-weight-loss-drugs-ozempic-wegovy-show-promise-for-diabetic-patients-undergoing-hip-",
            "time_published": "20240212T171558",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Preliminary findings presented at an orthopedic surgeons' meeting on Monday indicate that new drugs designed for diabetes and weight loss could benefit patients undergoing hip replacement.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.052974,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "0.177669",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The town that Ozempic and Wegovy built",
            "url": "https://www.economist.com/1843/2024/02/12/the-town-that-ozempic-and-wegovy-built",
            "time_published": "20240212T163218",
            "authors": [
                "The Economist"
            ],
            "summary": "Mads DamkjÃ¦r, a friendly civil servant with a parka and a side parting, took his foot off the gas as he pointed to the factory that is making fat people thin.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/1843_20240212_1843_OZEMPIC_02_RT.jpg",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.134965,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CABGY",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "0.06772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "0.000897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "0.000897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.455525",
                    "ticker_sentiment_score": "0.158172",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "-0.014535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "-0.014535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.018597",
                    "ticker_sentiment_score": "-0.014535",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/02/12/2827686/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240212T162200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 12 February 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.151495,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.043091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.043091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.784481",
                    "ticker_sentiment_score": "0.24234",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's major shareholder plans to invest about $35 bn by 2030 | Company News",
            "url": "https://www.business-standard.com/companies/news/novo-nordisk-s-major-shareholder-plans-to-invest-about-35-bn-by-2030-124021201413_1.html",
            "time_published": "20240212T152729",
            "authors": [
                "Reuters"
            ],
            "summary": "Novo Nordisk's major shareholder plans to invest about $35 bn by 2030 Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-02/05/full/1707157742-4299.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.152348,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.12188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "0.391901",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Three Stocks: AbbVie, Viking Therapeutics, and Cloudflare",
            "url": "https://moneymorning.com/2024/02/12/three-stocks-abbvie-viking-therapeutics-and-cloudflare/",
            "time_published": "20240212T150046",
            "authors": [],
            "summary": "Just like we spoke about in early December, AbbVie ( ABBV ) is starting to feel an acquisition spree it was on last year. And just as we said, long-dated put options back then would've yielded well now that the company lowered its guidance this morning due to the \"dilutive impact\" of its ...",
            "banner_image": null,
            "source": "Money Morning",
            "category_within_source": "RSS",
            "source_domain": "moneymorning.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.265342,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NET",
                    "relevance_score": "0.285526",
                    "ticker_sentiment_score": "0.168033",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.350899",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.285526",
                    "ticker_sentiment_score": "0.120585",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  is a Top Stock for the Long-Term",
            "url": "https://www.zacks.com/stock/news/2224747/why-novo-nordisk-nvo-is-a-top-stock-for-the-long-term",
            "time_published": "20240212T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9973"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.320391,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.186259",
                    "ticker_sentiment_score": "0.228457",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Value Stocks With Monster Yields",
            "url": "https://www.fool.com/investing/2024/02/12/2-value-stocks-with-monster-yields/",
            "time_published": "20240212T141500",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two low-priced large-cap stocks sport ginormous yields.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764890%2Fvalue-vs-price.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.15026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.088091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.378777",
                    "ticker_sentiment_score": "-0.032375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.088091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.222327",
                    "ticker_sentiment_score": "-0.02711",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Magic Run Continues Even With Increasing Competition",
            "url": "https://www.fool.com/investing/2024/02/12/novo-nordisks-magic-run-continues-even-with/",
            "time_published": "20240212T141500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk's Q4 earnings were rock solid as momentum in the diabetes and obesity markets continued to fuel growth.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764199%2Fblood-pressure-doctor-senior-citizen-1.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.32476,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.039023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "0.530137",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.039023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PMNT",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.305091",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37068324/novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-w",
            "time_published": "20240212T135745",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The unprecedented demand for weight loss drugs, including Novo Nordisk A/S's NVO Wegovy and Eli Lilly And Co's LLY Zepbound, has created a supply crunch, leaving patients struggling to access these injectable treatments.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.146812,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.160399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.130414",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.321378",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market Like Zacks: Costco, GigaCloud, Novo Nordisk in Focus",
            "url": "https://www.zacks.com/stock/news/2224537/beat-the-market-like-zacks-costco-gigacloud-novo-nordisk-in-focus",
            "time_published": "20240212T130300",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fa/1036.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                }
            ],
            "overall_sentiment_score": 0.223012,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ENPH",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.089237",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.101725",
                    "ticker_sentiment_score": "0.107876",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.101286",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.089237",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GCT",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.312969",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICE",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.0603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.0603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LAKE",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.246269",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ETN",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.124394",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STNE",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.246269",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2024/02/12/2827422/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20240212T121300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 12 February 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.94121",
                    "ticker_sentiment_score": "0.177803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is iShares International Equity Factor ETF  ( INTF )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2224472/is-ishares-international-equity-factor-etf-intf-a-strong-etf-right-now",
            "time_published": "20240212T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default346.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.204816,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.039936",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "-0.022007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "-0.022007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "-0.02492",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names",
            "url": "https://www.fool.com/investing/2024/02/12/wall-street-next-stock-split-stocks-familiar-names/",
            "time_published": "20240212T100600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready for round two!",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764705%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.219078,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.05986",
                    "ticker_sentiment_score": "0.09711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.025665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.207317",
                    "ticker_sentiment_score": "0.107309",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.111324",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.025665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.025665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.092276",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.148915",
                    "ticker_sentiment_score": "0.110666",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?",
            "url": "https://www.fool.com/investing/2024/02/12/could-lillys-zepbound-become-worlds-best-seller/",
            "time_published": "20240212T100300",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Everyone is excited about Zepbound, from patients to investors...",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764827%2Fgettyimages-three-investors-look-at-a-computer_in-office.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.1742,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.070678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390904",
                    "ticker_sentiment_score": "0.270324",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.070678",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk",
            "url": "https://www.marketwatch.com/story/this-grouping-of-stocks-has-actually-kept-up-with-the-magnificent-seven-and-with-a-lot-less-risk-42521498",
            "time_published": "20240212T092300",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.",
            "banner_image": "https://images.mktw.net/im-43871749?width=700&height=558",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.105881,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.060401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.060401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.060401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.060401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.060401",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "-0.195965",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "-0.195965",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "-0.121546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "-0.042919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "-0.121546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "-0.195965",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest' - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/02/37062937/ozempic-makers-parent-company-to-invest-7b-annually-by-2030-we-have-more-money-than-ever-to-invest",
            "time_published": "20240212T081207",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk NVO, plans to ramp up its annual investments to $7 billion by 2030. What Happened: The investment firm, which manages the assets of the Novo Nordisk Foundation, intends to increase its annual investments from $3 ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-maker-Novo-Nordisk_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.149817,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.493128",
                    "ticker_sentiment_score": "0.081793",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.647216",
                    "ticker_sentiment_score": "0.187047",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How Mindsets Drive Processes In The World's Most Valuable Firms",
            "url": "https://www.forbes.com/sites/stevedenning/2024/02/11/how-mindsets-drive-processes-in-the-worlds-most-valuable-firms/",
            "time_published": "20240211T235049",
            "authors": [
                "Steve Denning"
            ],
            "summary": "Whether firms know it or not, management embodies both mindsets and processes. For the century after Frederick Taylor declared in 1911 that \"the system must come before the man,\" processes dominated. Today, in the world's most valuable and fastest growing firms, the opposite is the case.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ca5ec19725de52937812f0/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.228282,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.112401",
                    "ticker_sentiment_score": "0.042611",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "0.023576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "-0.006729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "0.023576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "0.023576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "0.08953",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.",
            "url": "https://www.fool.com/investing/2024/02/11/abbott-laboratories-is-the-latest-company-to-get-i/",
            "time_published": "20240211T180600",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764003/digital-health-wellness-exercise-nutrition-track-data-doctor.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.189493,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HIMS",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "-0.053033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.135657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.147552",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?",
            "url": "https://www.fool.com/investing/2024/02/11/novo-nordisk-is-scaling-a-barrier-to-growth-should/",
            "time_published": "20240211T172500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Even more revenue is on the way from additional sales of Wegovy.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764279/tablet-thinking-office.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.161313,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.048621",
                    "ticker_sentiment_score": "0.061823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.048621",
                    "ticker_sentiment_score": "0.008959",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.416844",
                    "ticker_sentiment_score": "0.16777",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.",
            "url": "https://www.fool.com/investing/2024/02/11/dont-worry-about-novo-nordisks-premium-stock-price/",
            "time_published": "20240211T151500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk stock is up more than 70% in the past year thanks to the success of Ozempic, Rybelsus, and Wegovy.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764236%2Fdoctors-white-coat-healthcare.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.293397,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.120322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.596532",
                    "ticker_sentiment_score": "0.503174",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.079",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited",
            "url": "https://www.fool.com/investing/2024/02/10/novo-nordisk-just-gave-investors-165-billion-more/",
            "time_published": "20240210T145300",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764217%2Fclean-room-in-pharmaceutical-factory-with-technician.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.216778,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.441424",
                    "ticker_sentiment_score": "0.117023",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.684036",
                    "ticker_sentiment_score": "0.368983",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Weight loss drugs are still hard to find - but Novo Nordisk and Eli Lilly are trying to change that",
            "url": "https://www.cnbc.com/2024/02/10/weight-loss-drugs-novo-nordisk-eli-lilly-are-tackling-supply-issues.html",
            "time_published": "20240210T130001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107364694-17062136162023-11-21t141914z_82196440_rc2oh4ah9cpp_rtrmadp_0_health-obesity-novo-nordisk.jpeg?v=1707513174&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.011957,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.028155",
                    "ticker_sentiment_score": "0.126811",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.028155",
                    "ticker_sentiment_score": "-0.051166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.140076",
                    "ticker_sentiment_score": "-0.015014",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.028155",
                    "ticker_sentiment_score": "0.081038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.353639",
                    "ticker_sentiment_score": "0.078471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.028155",
                    "ticker_sentiment_score": "-0.009342",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.056275",
                    "ticker_sentiment_score": "0.072015",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Stocks That Could Trounce the Market in 2024",
            "url": "https://www.fool.com/investing/2024/02/10/3-stocks-that-could-trounce-the-market-in-2024/",
            "time_published": "20240210T114900",
            "authors": [
                "David Jagielski",
                "and Prosper Junior Bakiny",
                "Keith Speights"
            ],
            "summary": "These stocks appear to have what it takes to beat the market this year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764580/person-smiling-and-looking-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998932"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.285154,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.196132",
                    "ticker_sentiment_score": "0.143278",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.157483",
                    "ticker_sentiment_score": "0.154214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.153045",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.096768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.234307",
                    "ticker_sentiment_score": "0.179938",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/markets/equities/24/02/37043860/s-p-500-hits-5-000-magnificent-7-tops-13-trillion-commercial-real-estate-cracks-emerge-the-week-",
            "time_published": "20240209T210819",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "The S&P 500 index surged past the 5,000-point threshold by the week's end, setting new record highs on the optimism surrounding artificial intelligence. Both the S&P 500 and the Nasdaq 100 celebrated their 14th positive week out of the last 15, showcasing the resilience of the winter rally.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wall-Street-.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.157472,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.379435",
                    "ticker_sentiment_score": "0.252457",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "-0.060031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.044833",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "-0.060031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.090253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.096429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "-0.003743",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.081232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.058219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.180448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "-0.090253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSHZF",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.022857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.15697",
                    "ticker_sentiment_score": "0.058219",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What to think about 'Peak 65'",
            "url": "https://www.marketwatch.com/story/what-to-think-about-peak-65-d23f2413",
            "time_published": "20240209T190600",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also: Strategies to build a retirement nest egg and make it last, and a different way for investors to play the weight-loss-drug craze.",
            "banner_image": "https://images.mktw.net/im-74524387?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.095345,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.071851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.012989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "-0.025551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.022061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WEWOW",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.093845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.045374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Really Just the Magnificent 7 Propping Up This Market?",
            "url": "https://www.zacks.com/commentary/2224329/is-it-really-just-the-magnificent-7-propping-up-this-market",
            "time_published": "20240209T183200",
            "authors": [
                "Bryan Hayes"
            ],
            "summary": "The choir has been preaching that these seven stocks are holding up an overall weak market.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/87/3588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.283167,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.152178",
                    "ticker_sentiment_score": "0.071612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.152178",
                    "ticker_sentiment_score": "0.071612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.152178",
                    "ticker_sentiment_score": "0.148603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.152178",
                    "ticker_sentiment_score": "0.063802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "World's Richest Woman Loses $7 Billion On L'Oreal's Worst Day Since 2008",
            "url": "https://www.forbes.com/sites/dereksaul/2024/02/09/worlds-richest-woman-loses-7-billion-on-loreals-worst-day-since-2008/",
            "time_published": "20240209T180459",
            "authors": [
                "Derek Saul"
            ],
            "summary": "The net worth of the world's wealthiest woman Francoise Bettencourt Meyers fell precipitously Friday as shares of L'Oreal, the French beauty company about one-third owned by the billionaire and her family, registered their worst single-day performance since the Great Recession.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c668e32d13684ce7a1b136/0x0.jpg?format=jpg&crop=3564,2003,x0,y157,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.002472,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.003682",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "-0.028714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "-0.028714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals",
            "url": "https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-llys-q4-earnings-nvo-nvs-mrks-ma-deals",
            "time_published": "20240209T153600",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976671"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.080745,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.291182",
                    "ticker_sentiment_score": "0.088229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOR",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.005453",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.244354",
                    "ticker_sentiment_score": "0.109061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.148121",
                    "ticker_sentiment_score": "0.043887",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.291182",
                    "ticker_sentiment_score": "0.037556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "-0.074089",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?",
            "url": "https://www.fool.com/investing/2024/02/09/these-2-stocks-are-trying-to-ride-the-ozempic-band/",
            "time_published": "20240209T114500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "There's room for multiple winners in the fast-growing weight-loss market.",
            "banner_image": "https://media.ycharts.com/charts/9a7dfc4b05a8112da29aeee9f1a537f2.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.109291,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "REGN",
                    "relevance_score": "0.104455",
                    "ticker_sentiment_score": "-0.018962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05234",
                    "ticker_sentiment_score": "-0.112999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.156123",
                    "ticker_sentiment_score": "0.142628",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Anti-obesity drug market on steady growth path in India, shows data | India News",
            "url": "https://www.business-standard.com/india-news/anti-obesity-drug-sales-in-india-clock-32-cagr-in-5-years-shows-data-124020900943_1.html",
            "time_published": "20240209T112200",
            "authors": [
                "Sohini Das"
            ],
            "summary": "Anti-obesity drug market on steady growth path in India, shows data Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2022-05/06/full/1651856419-8291.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.147283,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.277282",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month",
            "url": "https://www.fool.com/investing/2024/02/08/heres-why-merck-eli-lilly-and-novo-nordisk-stocks/",
            "time_published": "20240208T215600",
            "authors": [
                "Ryan Downie"
            ],
            "summary": "Investors are still excited about obesity treatments and weight-management drugs.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764656%2Fgettyimages-663845678-600x400-bf06395.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.238796,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.399506",
                    "ticker_sentiment_score": "0.12975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "0.101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.227826",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.177584",
                    "ticker_sentiment_score": "0.195563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stocks: 5 Biggest Companies in 2024",
            "url": "https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-10-pharmaceutical-companies/",
            "time_published": "20240208T211500",
            "authors": [
                "Meagen Seatter"
            ],
            "summary": "Companies in this sector are constantly researching and creating innovative treatments for various medical conditions, including immuno-oncology, neurology and rare diseases. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.",
            "banner_image": "https://investingnews.com/media-library/pills-spilling-out-of-a-pill-bottle-on-a-yellow-background.jpg?id=32933343&width=1200&height=800&quality=85&coordinates=65%2C0%2C66%2C0",
            "source": "Investing News Network",
            "category_within_source": "n/a",
            "source_domain": "investingnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.129917,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.038373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.045406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.083975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.070123",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.089865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.111754",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze",
            "url": "https://www.marketwatch.com/story/viking-therapeutics-may-offer-investors-a-cheap-entry-to-the-weight-loss-drug-craze-8d5d623a",
            "time_published": "20240208T191800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Stock is trading at $28 compared with Eli Lilly's $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.",
            "banner_image": "https://images.mktw.net/im-832731/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.196705,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.306761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.158504",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.218866",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Going On With Eli Lilly Stock Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/02/37011034/whats-going-on-eli-lilly-stock-thursday",
            "time_published": "20240208T153658",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Since Monday, Eli Lilly And Co LLY shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a whopping $690 billion ( roughly ) . Thursday, shares are trading with a session volume of 25.301K compared to an average volume of 3.277 million, as per data from ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eli-Lilly_3.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.082912,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.753715",
                    "ticker_sentiment_score": "0.253242",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.179932",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.192315",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "-0.179932",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.172805",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.172805",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "2 Cathie Wood Stocks With Jaw-Dropping Growth Potential",
            "url": "https://www.fool.com/investing/2024/02/08/2-cathie-wood-stocks-with-jaw-dropping-growth-pote/",
            "time_published": "20240208T153000",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two platform biotechs could revolutionize the field of biologically based products.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764447%2Fhealthcare.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.270415,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.142511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.099042",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.187221",
                    "ticker_sentiment_score": "0.216158",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.187221",
                    "ticker_sentiment_score": "0.158936",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.146547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.146547",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For",
            "url": "https://www.forbes.com/sites/tylerroush/2024/02/08/pharma-ceos-will-testify-today-over-prescription-drug-prices-heres-what-to-watch-for/",
            "time_published": "20240208T152829",
            "authors": [
                "Ty Roush"
            ],
            "summary": "Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders ( I-Vt. ) , who has accused the firms of overcharging Americans for prescription drugs.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c4f258ec6a6b22d51c0160/0x0.jpg?format=jpg&crop=3696,2078,x0,y378,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.152983",
                    "ticker_sentiment_score": "0.053732",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "0.042438",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "-0.008213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.227716",
                    "ticker_sentiment_score": "-0.021698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "0.042438",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prediction: 2 Stocks That Could Trounce the Market",
            "url": "https://www.fool.com/investing/2024/02/08/prediction-2-stocks-that-could-trounce-the-market/",
            "time_published": "20240208T150000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "They have done it before.",
            "banner_image": "https://media.ycharts.com/charts/e15bf0846b51c8b52cdc3347650dbbd0.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.714479"
                }
            ],
            "overall_sentiment_score": 0.205126,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.450768",
                    "ticker_sentiment_score": "0.24971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.413878",
                    "ticker_sentiment_score": "0.269869",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.051208",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2024/02/08/2826164/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20240208T145500",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 8 February 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.94121",
                    "ticker_sentiment_score": "0.177803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "InnovationRx: New York's Digital Health Optimism",
            "url": "https://www.forbes.com/sites/katiejennings/2024/02/08/innovationrx-new-yorks-digital-health-optimism/",
            "time_published": "20240208T134915",
            "authors": [
                "Katie Jennings"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. t's no surprise that total venture funding for New York-based digital health startups was down in 2023.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c4d7844d58c2965361419d/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.078802,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.246507",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RTA1:MU",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.157346",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.159051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CNC",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.246507",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KNBWF",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.137341",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KYKOF",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "0.137341",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.050786",
                    "ticker_sentiment_score": "-0.364901",
                    "ticker_sentiment_label": "Bearish"
                }
            ]
        },
        {
            "title": "How Important Are Ozempic and Wegovy to Novo Nordisk's Business?",
            "url": "https://www.fool.com/investing/2024/02/08/how-important-are-ozempic-wegovy-to-novo-nordisk/",
            "time_published": "20240208T111500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Does a lack of diversification make Novo Nordisk a risky buy?",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763866%2Fnovo-nordisk-quarterly-results-shown-in-a-chart.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.353679,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.493442",
                    "ticker_sentiment_score": "0.425443",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.152259",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.260189",
                    "ticker_sentiment_score": "0.152259",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Minnesota and Eli Lilly settle insulin price-gouging lawsuit. Deal will hold costs to $35 a month",
            "url": "https://apnews.com/article/minnesota-insulin-lawsuit-lilly-7733d1402ed4b2411d6142a494fe3f23",
            "time_published": "20240207T223900",
            "authors": [
                "STEVE KARNOWSKI"
            ],
            "summary": "ST. PAUL, Minn. ( AP ) - Minnesota has with Eli Lilly and Co. in a price gouging lawsuit against the country's three biggest insulin manufacturers that guarantees that Minnesotans can now buy Lilly-produced insulin for only $35 a month for the next five years, Attorney General Keith Ellison ...",
            "banner_image": "https://dims.apnews.com/dims4/default/f2515dc/2147483647/strip/true/crop/7252x4831+0+3/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F01%2Ff7%2Fefe4fe914ccb4449dff9f228f541%2F4c82edc6575749959a713826a4f6a439",
            "source": "Associated Press",
            "category_within_source": "Business",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.016558,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.191929",
                    "ticker_sentiment_score": "0.067841",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "-0.015032",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "-0.015032",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Agrees To Donate Insulin To Clinics Across Minnesota In Lawsuit Settlement",
            "url": "https://www.forbes.com/sites/caileygleeson/2024/02/07/eli-lilly-agrees-to-donate-insulin-to-clinics-across-minnesota-in-lawsuit-settlement/",
            "time_published": "20240207T214325",
            "authors": [
                "Cailey Gleeson"
            ],
            "summary": "Minnesota Attorney General Keith Ellison announced Wednesday that pharmaceutical giant Eli Lilly will donate insulin to clinics around the state for the next five years-and keep a $35 price cap for all patients in the state-to settle allegations that it \"deceptively priced\" its insulin products, ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c3f94524bfa0ea5156617e/0x0.jpg?format=jpg&crop=2565,1442,x0,y30,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.108702,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.079921",
                    "ticker_sentiment_score": "-0.092493",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.236588",
                    "ticker_sentiment_score": "-0.049454",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.236588",
                    "ticker_sentiment_score": "-0.049454",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns - Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/news/24/02/36986742/catalents-bloomington-plant-making-novo-nordisks-obesity-drug-faces-fda-scrutiny-regarding-drug-manu",
            "time_published": "20240207T170212",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has encountered manufacturing challenges and drug shortages for its diabetes and weight loss drugs due to unprecedented demand for Wegvoy and Ozempic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.064784,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.63878",
                    "ticker_sentiment_score": "0.104043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.566143",
                    "ticker_sentiment_score": "0.171378",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Riding on Novo Nordisk's semaglutide, India's weight-loss market triples in size in 2 years",
            "url": "https://www.moneycontrol.com/news/trends/health/riding-on-novo-nordisks-semaglutide-indias-weight-loss-market-triples-in-size-in-2-years-12216101.html",
            "time_published": "20240207T151515",
            "authors": [],
            "summary": "Semgalutide has almost 66 percent of the market share in the anti-obesity segment.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/08/Lupin7.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.172982,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.22335",
                    "ticker_sentiment_score": "0.107776",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations - Catalent  ( NYSE:CTLT ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36981422/ctlt-alert-monsey-law-firm-of-wohl-fruchter-llp-investigating-catalent-inc-for-potential-securitie",
            "time_published": "20240207T141345",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "MONSEY, N.Y., Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. CTLT ( \"Catalent\" ) has violated federal securities laws based on a report by Bloomberg alleging that inspectors from the U.S.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.045064,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.655281",
                    "ticker_sentiment_score": "0.233343",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.363388",
                    "ticker_sentiment_score": "0.093955",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Catalent  ( CTLT )  Rides on Acquisition Offer From Novo Holdings",
            "url": "https://www.zacks.com/stock/news/2222342/catalent-ctlt-rides-on-acquisition-offer-from-novo-holdings",
            "time_published": "20240207T125100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.284881,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "UHS",
                    "relevance_score": "0.370418",
                    "ticker_sentiment_score": "0.173512",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.300394",
                    "ticker_sentiment_score": "0.246045",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.614697",
                    "ticker_sentiment_score": "0.568144",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.370418",
                    "ticker_sentiment_score": "0.383798",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies",
            "url": "https://www.prnewswire.com/news-releases/scion-life-sciences-launches-with-oversubscribed-310-million-fund-to-create-and-build-exceptional-biotech-companies-302055568.html",
            "time_published": "20240207T110000",
            "authors": [
                "Scion Life Sciences"
            ],
            "summary": "Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2336065/Scion_Life_Sciences_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.294848,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYRX",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.073431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.085264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNTA",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.046255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.085264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRML",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STOK",
                    "relevance_score": "0.054175",
                    "ticker_sentiment_score": "0.070781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.027103",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's parent invests in India's Manipal hospital chain",
            "url": "https://www.moneycontrol.com/news/world/novo-nordisks-parent-invests-in-indias-manipal-hospital-chain-12207891.html",
            "time_published": "20240207T012138",
            "authors": [],
            "summary": "\"It ( the investment ) represents our commitment towards filling the gap between the enormous demand and underserved healthcare infrastructure in India,\" Novo Holdings said in a statement.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/08/FMCG.png?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.190237,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MFCSF",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.257804",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.14272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.257804",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.413199",
                    "ticker_sentiment_score": "0.357642",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Drug shortages may mean difference between life and death for some US patients, experts say",
            "url": "https://www.cnn.com/2024/02/06/health/drug-shortages/index.html",
            "time_published": "20240207T011300",
            "authors": [
                "Jen Christensen"
            ],
            "summary": "When T.J. Grimm and his team at University Hospitals Cleveland Medical Center put in their nightly orders to fill customers' medications, they're never really sure that the orders will actually get filled.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231129135934-fda-headquarters-file-2020.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.140452,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.024673",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.024673",
                    "ticker_sentiment_score": "0.189649",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Is What Whales Are Betting On Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/36964264/this-is-what-whales-are-betting-on-novo-nordisk",
            "time_published": "20240206T193120",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 28 trades. If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.075577,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "-0.245489",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781119",
                    "ticker_sentiment_score": "0.203723",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes",
            "url": "https://www.cnbc.com/2024/02/06/healthy-returns-novo-nordisk-eli-lilly-tackle-weight-loss-drug-supply-woes.html",
            "time_published": "20240206T191321",
            "authors": [
                "Ashley Capoot",
                "Annika Kim Constantino"
            ],
            "summary": "Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277200-16903924192023-03-29t000000z_303454265_rc2w30aoohoj_rtrmadp_0_usa-health.jpeg?v=1693569721&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.059608,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.038101",
                    "ticker_sentiment_score": "0.021243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.113956",
                    "ticker_sentiment_score": "-0.010193",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.367141",
                    "ticker_sentiment_score": "-0.02899",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2024/02/06/2824666/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20240206T184300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 6 February 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.94121",
                    "ticker_sentiment_score": "0.177803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo invests in Manipal hospitals as it aims to expand Asia footprint",
            "url": "https://www.business-standard.com/companies/news/novo-invests-in-manipal-hospitals-as-it-aims-to-expand-asia-footprint-124020601004_1.html",
            "time_published": "20240206T181803",
            "authors": [
                "Reuters"
            ],
            "summary": "Novo Holdings, which is owned by Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, the maker of blockbuster obesity drug Wegovy and diabetes treatment Ozempic",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2020-11/05/full/1604591555-1386.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.266368,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MFCSF",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.272776",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.162231",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.272776",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.649352",
                    "ticker_sentiment_score": "0.51349",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease",
            "url": "https://www.cnbc.com/2024/02/06/eli-lilly-weight-loss-drug-may-treat-fatty-liver-disease.html",
            "time_published": "20240206T170601",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The results add to a long list of potential health benefits of tirzepatide besides helping patients shed significant pounds and regulate blood sugar.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107368557-17069062502023-12-13t123425z_1803569422_rc26v4aidh6r_rtrmadp_0_health-obesity-telehealth.jpeg?v=1706906310&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.014638,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "-0.066998",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales",
            "url": "https://www.zacks.com/stock/news/2221913/eli-lilly-lly-q4-earnings-beat-mounjaro-zepbound-drive-sales",
            "time_published": "20240206T154800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.177494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337951",
                    "ticker_sentiment_score": "0.152966",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARQT",
                    "relevance_score": "0.219099",
                    "ticker_sentiment_score": "0.025828",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.126284",
                    "ticker_sentiment_score": "0.035026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.188437",
                    "ticker_sentiment_score": "0.119642",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tesla Now Worth $110 Billion Less Than Weight Loss Drug Maker Eli Lilly",
            "url": "https://www.forbes.com/sites/dereksaul/2024/02/06/tesla-now-worth-110-billion-less-than-weight-loss-drug-maker-eli-lilly/",
            "time_published": "20240206T153039",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Out with electric vehicles, in with weight loss drugs: Investors have ditched one-time favorite Tesla for pharmaceutical giant Eli Lilly, as the early days of long-established Eli Lilly's diabetes and weight loss drugs deliver explosive profits.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c2504a149426c624daff3c/0x0.jpg?format=jpg&crop=3274,1842,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.064922,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.047819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.010156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.6338",
                    "ticker_sentiment_score": "0.098673",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.047819",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zepbound Maker Eli Lilly Forecasts Strong Profits Amid Rollout Of Weight Loss Drug",
            "url": "https://www.forbes.com/sites/roberthart/2024/02/06/zepbound-maker-eli-lilly-forecasts-strong-profits-amid-rollout-of-weight-loss-drug/",
            "time_published": "20240206T124144",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its diabetes drug Mounjaro and newly-approved weight loss drug Zepbound.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c22893521e6c1f4f9f201f/0x0.jpg?format=jpg&crop=2621,1473,x0,y120,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.224239,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.096927",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Invesco S&P International Developed Quality ETF  ( IDHQ )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2221500/is-invesco-sp-international-developed-quality-etf-idhq-a-strong-etf-right-now",
            "time_published": "20240206T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default177.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.2106,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.10562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.065933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.065933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.065933",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/02/06/2823974/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240206T072000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "BagsvÃ¦rd, Denmark, 6 February 2024 - The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion will be initiated on 6 February 2024. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.1 billion in accordance ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.091293,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "0.055277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "0.055277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.719473",
                    "ticker_sentiment_score": "0.127509",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novartis to bolster its oncology portfolio with acquisition of MorphoSys",
            "url": "https://www.marketwatch.com/story/novartis-to-bolster-its-oncology-portfolio-with-acquisition-of-morphosys-6b167583",
            "time_published": "20240206T040500",
            "authors": [
                "Mike Murphy"
            ],
            "summary": "Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).",
            "banner_image": "https://images.mktw.net/im-00708648/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.226807,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MOR",
                    "relevance_score": "0.601928",
                    "ticker_sentiment_score": "0.609989",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167322",
                    "ticker_sentiment_score": "-0.356895",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "0.335643",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        }
    ]
}